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Abstract
Drug-eluting stents have revolutionized the field of interventional cardiology and with the advent
of their second-generation, percutaneous coronary intervention with drug-eluting stents is the
clinically preferred method. These stents have shown remarkable performance in reducing
neointimal hyperplasia and thus, clinical manifestation of restenosis. Despite significant
technological advances in DES, high-risk patient populations are still affected by in-stent
restenosis. Diabetes and hypertension are the two most common patient-specific complications that
result in the development of restenosis even in DES era. Currently, percutaneous interventional
approaches are not designed specifically to address the pathophysiological progression of
restenosis in diabetic and hypertensive patients and as a result these high-risk patient cohorts
continue to experience poorer prognosis. Absence of diabetes and/or hypertension specific stents
or percutaneous interventional approaches is in part due to less emphasized basic research on
understanding cellular response in diabetes and hypertension associated conditions owing to the
lack of in vitro testing platforms capable of capturing the clinically relevant cellular response.
Diabetes is characterized by hyperglycemia, insulin resistance and requires external insulin
administration. Chronic high-glucose acclimation resulted in significantly greater phenotypic
modulation of vascular smooth muscle cells under clinically relevant loading. In the current
dissertation, an in vitro model has been developed simulating conditions observed in diabetic and
hypertensive patients to better evaluate the response of VSMC, predict in-stent restenosis and
evaluate the efficacy of sirolimus. This model combined insulin administration and elevated
circumferential strain associated with diabetes and hypertension respectively, with low wall-shear
stress induced by the presence of stent struts. Cellular response under these conditions closely
simulates clinical conditions, in comparison to the current gold standard of conventional static
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cultures. Additionally, this model allows for a better understanding of VSMC response subjected
to diabetes and hypertension simulated conditions during dynamic mechanical loading.
Using this novel approach of combining mechanical loading and patient-specific biochemical
environment, this dissertation successfully demonstrates significantly greater phenotypic
modulation of chronic high-glucose acclimated rat aortic smooth muscle cells due to insulin
administration under clinically relevant mechanical forces. Evaluation of phenotypic modulation
was performed by comparing cell-cycle progression, induction of apoptosis, expression of
contractile-state associated proteins all of which demonstrated significantly greater modulation
with insulin administration under dynamic loading (p <0.0001 for all).
Hypertension-associated elevated mechanical strain resulted in a proliferative phenotype (p <
0.001), induced apoptosis (p < 0.001) and reduced the expression of contractile state proteins (p <
0.001). Subjecting cells to insulin administration under hypertension-associated cyclic mechanical
strain with low-flow shear stress further enhances dedifferentiation of RASMCs. The combined
effects of hypertensive mechanical forces and insulin administration associated with diabetes
management significantly affected cell response where cells under hypertensive loading during
insulin administration demonstrated significantly greater percentage of cells in the S (p< 0.0001)
and G2/M phase (p< 0.0001). These conditions also resulted in significantly reduced expression of
contractile markers (p-value < 0.0001 for αSM-actin and SM22α). As a model application,
sirolimus a commonly used drug in stents was evaluated under diabetic-hypertensive conditions.
Lower efficacy of sirolimus was observed under these conditions which necessitates development
and identification of novel drugs and therapeutic targets, to address the greater phenotypic
modulation associated with these patient-specific conditions and may also explain the poorer
outcomes of sirolimus -eluting stents in diabetic patients requiring insulin administration and
presenting with hypertension. The proposed cell-response evaluation model provides a tool to
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investigate cellular and molecular mechanisms, testing novel drug and identifying important
molecular targets for the specific patient cohort.
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Chapter 1: Background
1.1 Blood Vessel Anatomy:
The structure of the blood vessel has been anatomically structured to support multitude of functions
including nutrient transport and gas exchange. Within the systemic circulation system, arteries
carry oxygenated blood away from the heart downstream via smaller vessels. Arterioles, the
smallest arteries, branch into tiny capillaries which are the site of nutrient and waste exchange
owing to their thin structure. Similarly, deoxygenated blood is transported back to the heart via
venules, veins and ultimately back to the heart to enter the pulmonary circuit. Different types of
blood vessels vary slightly in their structures, but they share the same general features. Arteries and
arterioles have thicker walls than veins and venules because they are closer to the heart and receive
blood that is surging at a far greater pressure. In the larger vessels, blood transport occurs relatively
quickly which, in addition to thicker vessel walls, results in poorer exchange of nutrients and waste.
Anatomically, this problem is addressed by vasa vasorum or vessels of the vessel which
fundamentally provide the nutrient exchange for the cells of larger blood vessels. Owing to
differences in pressure, vasa vasorum are located closer to the lumen in veins whereas in the outer
layer for arteries (1).
Blood vessels closer to the heart are known as elastic or conducting arteries typically larger than
10 mm in diameter and rich in elastic fibers. Moving away from the heart, the elastin content
decreases while the amount of vascular smooth muscle cell increases resulting in muscular or
distributing arteries ranging from 0.1 to 10 mm. Downstream these arteries further split into
arterioles and eventually capillaries. A blood vessel is structured into three main layers or tunics:
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Intima, Media and Externa:
a. Tunica Intima: As the innermost layer of a blood vessel, the intima is comprised of simple
squamous epithelium called endothelium, which is a continuous layer throughout the entire
vascular system, including the chambers of the heart. The endothelium is responsible for
multitude functionalities such as regulating capillary exchange, altering blood flow through
endothelin mediated vascular smooth muscle cell contraction, nitric oxide mediated
vascular tone regulation among others. The endothelial monolayer is bound to the basement
membrane or basal lamina (~80 nm thick) that effectively provides strength while maintain
flexibility and permits materials to pass through owing to its permeable nature. The
basement membrane primarily consists of type IV collagen and laminin. The intimal layer
in aorta and coronary arteries may also include a sub-endothelial layer of connective tissue
and axially oriented smooth muscle cells. Endothelial cells are usually flat and elongated
in the direction of the blood flow, often about 0.2-0.5 µm thick, 10-15 µm wide and 25-50
µm long. Cells are interconnected by both tight junctions and gap junctions which regulate
transport of substances across the endothelium and allow cell-cell communication via
transport of metabolites respectively (2). In a healthy blood vessel, an intact endothelium
ensures a non-thrombogenic luminal surface. The outer layer of tunica intima consists of
connective tissue comprising primarily of elastic fibers to provide flexibility and
collagenous fibers to provide mechanical strength. For larger arteries, a distinct elastic fiber
layer is also present towards the boundary with tunica media, known as internal elastic
lamina. Openings within this lamina permits exchange of materials between the tunics (1).
b. Tunica Media: The thickest layer of a blood vessel, the tunica media primarily consists of
vascular smooth muscle cells that are responsible for muscular contraction and relaxation
of the blood vessel, Type I, III and V collagen, and proteoglycans. The cells are supported
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by connective tissue consisting of elastic fibers or elastin mostly arranged in circular sheets
whereas presence of longitudinal fibers is more prominent towards the outer side of the
layer. The cellular layer is supported by a framework of collagenous fibers that also bind
to the inner and out tunics. Contraction and relaxation of circumferentially arranged
muscular cells maintains the vascular tone of a blood vessel through processes known as
vasoconstriction and vasodilation which are chemically and mechanically driven
phenomenon. Like endothelial cells, smooth muscle cells also communicate via gap
junctions. Their intracellular myofibrils are typically oriented along the axis of the cell. In
elastic arteries, the medial smooth muscle cells are organized into 5-15 µm-thick concentric
layers that are separated by thin fenestrated sheets of elastin, which supports radial
transport of metabolites (1)(2).

c. Tunica Externa (Adventitia): Separated from the medial layer by the external elastic
lamina, the outermost layer or adventitia comprises of collagenous fibers and fibroblasts.
Fibroblasts are responsible for regulating the connective tissue, particularly type I collagen.
The outermost layer of the externa is not distinctively visible but blends with the
surrounding connective tissue around the blood vessel. The thickest layer for veins and the
site for vasa vasorum in arteries, the outermost layer ensures stability and position of the
blood vessel and prevents over distension of the vessels.
1.2 Blood-vessel mechanical forces:
During a single cardiac cycle, oxygenated blood is transported in a pulsatile manner from the heart
to the aorta for distribution to the systemic circuit. Multiple forces act together in a healthy blood
vessel as a result of blood flow from the heart and can adjust according to the diseased state of the
vessel to ensure hemostasis. These forces can be from blood flow (shear), arterial distension and
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contraction (vascular tone) and hydrostatic fluid pressure. Application of these forces induce
stresses in the longitudinal, radial and circumferential directions and represents the intricate
interplay between solid mechanics and fluid dynamics of the blood vessel. As depicted in the image,
the radial pressure (P) in the lumen is balanced by circumferential tensile stress (σ) in the artery
wall and is defined by Laplace’s law, which assumed the blood vessel to be thin-cylinder, where
‘r’ is the radius and ‘h’ is thickness of the vessel (Figure 1).

Figure 1: Principle stresses for thin-wall cylinder with Laplace’s model
(Adapted and modified from Lee et al) (3)

In three-dimension, most biological materials exhibit non-linear mechanical behavior and as the
stress on a biological material is increased, the increment of strain for each increment of stress
decreases, so that the material becomes stiffer and is one of the reasons why angioplasty often
requires balloon pressures over 50 times greater than mean arterial blood pressures (3). Since blood
vessels are not made up of a single material, defining their mechanical behavior with a single
number is an oversimplification. Three-dimensionally, blood vessels have different arrangement of
collagen and elastin fibers that results in different stress-strain relationship depending upon the
direction of applied force or anisotropic and may require over 20 variables to accurately define the
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mechanical properties. Blood-vessels also have a time-dependent response to the applied forces
where if tensile stress is placed on the tissue, it will continue to elongate for some period of time
until a new equilibrium strain is reached and essentially demonstrate a time-dependence of stressstrain relationship called viscoelasticity. Prolonged balloon inflations beyond critical fracture point
and delayed elastic recoil are clinical cases where viscoelastic nature of the blood-vessel material
comes into play (3). For arterial wall, the intraluminal surface is subjected to mean pressures of
about 13.3 kPa (100 mmHg) and pulse pressure of ~ 5.3 kPa (40 mmHg). Physiologically, arterial
wall is subjected to < 10% circumferential strain whereas in the longitudinal direction, arteries are
stretched by 30-50% as confirmed by arterial contraction immediately after excision. The arterial
diameter varies by ~ 10% in addition to significant change in arterial length as well (4).
Blood flow through small vessels is defined by the Haagen-Poiseuille flow or laminar flow through
circular tubes where typical blood-flow rates are in the range of 300-400 mL/min. Behavior of fluid
flow is impacted by the diseased state of the vessel and it has been well established that areas of
low-wall shear stress or zones of no-flow are the primary sites of atherosclerotic lesion initiation
and progression (5). In general, fluid flow can be steady or unsteady in nature with steady flow
having a flow-velocity that does not alter with time while, time-dependent change occurs in
unsteady flow conditions (6). Larger arteries are sites of unsteady flow conditions whereas small
arteries and capillaries are considered to have steady flow conditions.
Flow through a cylindrical tube or vessel may be characterized as laminar, transitional or turbulent
which is a result of the various forces acting on the fluid. Through a cylindrical tube, flow particles
experience two primary forces – inertial and viscous forces. The ratio of these two forces is a
dimensionless constant defined as the Reynolds number (Re), where ρ is the fluid density (kg/cm3),
U is velocity (cm/s), d is diameter (cm) and µ is viscosity (dyne*sec/cm2) (7).
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{1}

A fluid volume entering a long tube has a flat velocity profile at the entrance of the tube and as
fluid moves into the tube and further away from the entrance, the velocity profile begins to have a
curvature near the wall and has a magnitude of zero at the wall (no slip condition) whereas the
profile at the center remains flat. Beyond an arbitrary point (defined as fully developed point or FD line), the fluid profile becomes parabolic. The section of the tube before the FD-line is called the
entrance length or flow development region. For laminar flow (Re < 1200), fluid is assumed to
move in concentric cylindrical shells and since the radial and tangential velocities are negligible,
fluid essentially remains the same radial position throughout the tube. Fluid enters the tube
(volumetric flow rate, Q) and its development is governed by two constraints: a. Due constant crosssectional area of the tube, the average velocity at any position along the tube is constant; and b.
Fluid particles adjacent to the wall are motionless with respect to the wall. The motionless “shell”
of fluid adjacent to the wall retards the motion of the next shell though shearing forces acting in the
direction opposite to the direction of flow and on the surface area of the shell resulting in shear
stress. Since the motion of the second shell is retarded by the first and in tandem subsequent shells
however, due to continuity constraint, the fluid near the center is accelerated to maintain the same
average velocity as that at the entrance (figure 2).
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Figure 2: Velocity profile through a straight tube. Image modified from original (7).
This simultaneous retardation and acceleration continues until the profile becomes parabolic at the
FD-line For laminar flow, the entrance length is given by ‘X’ (7).
X = 0.03d(Re)

{2}

For fully-developed laminar flow in a circular tube, the volumetric flow rate ‘Q’ thought the tube
is related to the pressure drop (Δp) measured over a length ‘L’ by the following expression (7):

{3}

where Q = volumetric flow rate; µ = fluid viscosity; d = tube diameter and is called the HaagenPoiseuille equation. Vascular walls are composed biologically active substances – cells and
extracellular matrix which are sensitive to shear stress exerted by the fluid flow. For the parabolic
profile, shear stress is defined as (7):

{4}
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where U is the velocity (cm/s), r is the radius of the blood vessel (cm) and µ is the fluid viscosity
(dynes*s/cm2). Wall shear stress can be estimated at the vessel-wall by the volumetric flow-rate for
a well-defined channel. Shear stress for a cylindrical vessel can be estimated by (7):

𝜏𝑊 =
Where

4𝜇𝑄
𝜋𝑅 3

{5}

‘𝜏W’ is the wall-shear stress (dynes/cm2), µ is the fluid viscosity (dynes*s/cm2), Q is the

volumetric flow-rate (cm3/sec) and R is the radius of the blood vessel (cm). Throughout the cardiac
system blood-vessels of differing radius exist however, typical mean arterial values of shear stress
range from 6 to 40 dynes/cm2 but can vary from 0 to well over 100 dynes/cm2 depending upon the
location in the vasculature (8,9). Shear stress is known to be maintained within the 10-20 dynes/cm2
range for most blood-vessels (10). Circumferential stress (σϑ)is defined by the following equation:

𝜎𝜃 =

𝑃𝑅
ℎ

{6}

where P = transmural pressure, R = radius; h = thickness whereas axial wall stress is defined by

𝜎𝑧 =

𝑓
𝜋ℎ(2𝑅 + ℎ)

{7}

As a consequence of elevated blood pressure, elevated levels of circumferential stress is exerted on
the vessel wall.
1.3 Atherosclerosis:
Coronary artery disease arising from atherosclerosis is the leading cause of death and morbidity
worldwide. Fundamentally, it is chronic inflammatory process of the arterial wall that occurs at
favorable sites due to disturbed laminar flow. Structurally, atherosclerotic lesions are symmetrical
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focal thickenings of the innermost layer of the artery consisting primarily of cells, connective-tissue
elements, lipids and debris. Blood-borne inflammatory and immune cells constitute an important
part of the atherosclerotic lesion with the remainder of the cells being endothelial and vascular
smooth muscle cells. Accumulation of lipid-laden cells, also called fatty-streaks, underneath the
endothelium precedes atheroma formation and is the earliest type of lesion consisting of only
monocyte-derive macrophages and T-lymphocytes with appearance as early as infants and young
childhood (11,12).
1.3.1 Endothelial dysfunction/denudation
The primary role of the endothelium is to maintain vascular homeostasis by a variety of regulatory
substances including nitric oxide (NO), prostaglandins, angiotensin and endothelin-1.
Pathophysiological observation in humans and animal models led to conclusions whereby
endothelial dysfunction/denudation is the earliest step of atherosclerosis.

When stimulated,

endothelial cells can upregulate cell-adhesion molecules such as intercellular adhesion molecule 1
(ICAM-1), vascular adhesion cell molecule 1 (VCAM-1), P-selectin to promote attachment and
rolling of circulating leukocytes and platelets. Common stimulants include elevated levels of lowdensity lipoprotein (LDL), very-low density lipoprotein (VLDL) and their oxidized forms, free
radicals from cigarette smoking, hypertension, Diabetes mellitus, elevated plasma homocysteine
concentrations or combination of these and other factors (13,14).
1.3.2 Acute and Chronic Inflammatory Response
Due to endothelial dysfunction/denudation, multiple vasoactive molecules, cytokines and growth
factors are secreted which, combined with greater endothelial permeability results in attachment,
rolling and diapedesis of monocytes at the site of dysfunction. Transmigration of monocytes, and
their subsequent differentiation to macrophages, results in the initiation of an inflammatory
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response at injured sites whereby macrophages uptake oxLDL resulting in the formation of foam
cells. Further, macrophages secrete cytokines and growth factors (MCF-1 & 7) which ultimately
encourage recruitment of more leukocytes from the circulation (15). As the inflammatory response
continues unabated in the presence of the stimulants, more and more inflammatory cells accumulate
at the injury site which further promote migration and proliferation of vascular smooth muscle cells
that eventually are intermixed with the area of inflammation to form an intermediate lesion (14).
1.3.3 Vascular smooth muscle cell migration
Secretion of growth factors and cytokines at the site of injury by inflammatory cells results in
phenotypic modulation, migration and proliferation of vascular smooth muscle cells to the lesion
site. As this response continues uninhibited, more and more VSMCs populate the lesion with
greater extracellular remodeling because of matrix metalloproteinase secretion by VSMCs and
macrophages. VSMCs are believed to confer plaque stability and their subsequent apoptosis at
advanced stages results in destabilization of the fibrous plaque which is more prone to rupture thus,
resulting in clinical manifestation of stroke or myocardial infarction (16).
1.3.4 Altered hemodynamics
Despite numerous contributing factors to the development of atherosclerosis, local hemodynamic
alterations play an extremely important role as atherosclerosis is a geometrically focal disease
preferentially affecting the outer edges of vessel bifurcations where wall shear stress is low. From
the earliest theories on co-localization of low shear stress and atherosclerosis, Caro et al (17)
successfully demonstrated that low shear stress invoked a pro-atherosclerotic response in
endothelial cells. Additional investigations subsequently supported the finding that low wall-shear
stress, directional changes in flow, flow separation and stasis promote atherosclerosis development
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since regions of the vascular tree free of these changes in flow were spared of atherosclerosis
(18,19).
Direct measurements and fluid mechanical models of the susceptible regions have revealed shear
values on the order of ± 4 dynes.cm-2 compared with greater than 12 dynes.cm-2 in the protected
areas. Atherosclerotic lesions have been reported to co-localize with regions of low shear stress
throughout the arterial tree from carotid artery bifurcation to the coronary, infrarenal and femoral
artery vasculatures (18,19).
Flow analysis and carotid endarectomy pathological sections have been reported to show the
greatest plaque thickness in the outer wall of the carotid sinus where flow shows stasis and shear is
low in magnitude and also demonstrates direction-reversal (20).
Biological manifestation of shear stress is primarily through its effect on endothelium and
eventually how the endothelial monolayer responds to alterations in shear stress. Shear stress
resulting from second-to-minute time-scale variation in flow increase secretion of prostacyclin (21)
and nitric oxide (22,23), both of which hinder platelet activation (24) and attenuate smooth muscle
cells proliferation (25). Physiological levels of shear stress (> 15 dynes.cm-2) decreases in vitro
endothelial cell turnover reducing basal rate of proliferation and the rate of apoptosis form growth
factor depletion (26,27). Whereas, low wall-shear stress (0-4 dynes.cm-2) has been reported to
promote endothelial cell proliferation and apoptosis (28) in addition to greater secretion of Platelet
derived growth factor (PDGF) (29). Greater expression of inflammatory mediators such as
Monocyte chemotactic protein-1 (MCP-1) (30) under low shear stress conditions further
demonstrates the impact of WSS whereby areas of low shear promote endothelial dysfunction and
support local inflammatory response. Essentially, shear stress alterations towards lower levels
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make a passive, non-thrombogenic surface of the endothelium a dynamically responsive vascular
element producing autocrine and paracrine factors (29).
1.3.5 Lesion progression
The initial lesion (type I) contains enough atherogenic lipoprotein to elicit an increase in
macrophages and formation of scattered macrophage foam cells and consists of the first
microscopically and chemically detectable lipid deposits in the intima and cellular reactions
associated with such deposits. The precursors of advanced lesions are divided into three
morphologically characteristic types. Type I, II and III are focal in nature, relatively small and
contain abnormal amounts of lipoproteins and cholesterol esters (31).
Type II lesions include fatty streaks, which may appear as yellow-colored streaks, patches or spots
on the intimal surface of arteries. These lesions are distinctly more defined than type I and consists
primarily of macrophage foam cells stratified in adjacent layers with intimal smooth muscle cells,
now containing lipid droplets as well. Location in the arterial tree in which type II lesions can be
observed are relatively constant and predictable out of which a sub-group of lesions start
progressing towards type III lesions and are called type IIa lesions. Interestingly, for coronary
arteries the location of type IIa lesions co-localizes with the early type I lesions during childhood.
The larger sub-group of type II lesions, which are thin and contain a few smooth muscle cells are
commonly categorized as the progression-resistant or Type IIb lesions (31).
The designation of Type II lesion applies only to lesions that form the morphological and chemical
bridge between type II lesions and atheromas (classified as type IV). These contain freer
cholesterol, fatty acid, sphingomyelin, lysolecithin and triglyceride than type II lesions. Early in
life, progression-prone locations shelter type IIa lesion and with aging these are the sites where
type III lesions and atheroma-type lesions are found (31).
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With type IV lesions or atheroma, a dense accumulation of extracellular lipid occupies an extensive
but well defined region of the intima and is known as the lipid core. The characteristic core appears
to develop from an increase and the consequent confluence of the small isolated pools of
extracellular lipid that characterize type III lesions. Lipid cores thicken the arterial wall and are
generally large enough to be visible when lesions are examined however, type IV lesions often fail
to narrow the lumen. Macrophages, macrophage foam cells and lymphocytes are more densely
concentrated in the lesion periphery. The tissue between the core and the surface endothelium
corresponds to the proteoglycan-rich layer of the intima (32).
When the nearly normal cover of lipid core later undergoes an increase in fibrous tissue (mainly
collagen), the lesion is then labeled type V which have prominent new fibrous connective tissue. If
the new tissue is part of a lesion with a lipid core (type IV), this type of morphology is referred to
as fibroatheroma or type Va lesion. A type V lesion in which the lipid core and other parts of the
lesion are calcified is called type Vb lesion and a type V lesion in which a lipid cores is absent and
lipid in general is minimal may be referred to as type Vc or fibrotic lesions. Type V lesions may
also develop fissures, hematoma and/or thrombus (32).
Morbidity and mortality from atherosclerosis is largely due to type IV and type V lesions in which
disruption of the lesion surface, hematoma or hemorrhage and thrombotic deposits have developed.
Type IV or V lesions with one or more of these features is classified as a type VI lesion. These can
be further categorized based on lesion features where, type VIa - disruption of the surface; type
VIb – hematoma or hemorrhage; type VIc – thrombosis. A type VIabc lesion contains all the
previously mentioned features (32).
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1.3.6 Imaging of Atherosclerosis:
Current standard imaging techniques are plaque-centric and recent developments in imaging
modalities the overall approach is moving more toward appreciation of the complexities that lead
to the development of atherosclerotic lesions. Majority of the patients afflicted with atherosclerosis
never experience overt clinical symptoms related to the disease which explains why more than 50%
of the patients who die suddenly because of coronary heart disease lack any presentation of
symptoms. Imaging techniques for atherosclerosis can be used to detect anatomic and physiological
consequences of long-standing atherosclerosis and thus, provide detail on plaque composition and
molecular activity in addition to estimation of biomechanical stresses.
Coronary angiography (Invasive): For diagnosis of atherosclerosis, invasive angiography is most
often performed where selective intubation of the coronary ostia is performed with a catheter
introduced via a peripheral sheath. A contrast dye is injected to produce radio-opaque contrast
under x-ray fluoroscopy. The high-diagnostic accuracy afforded by superior spatial (0.1-0.2 mm)
and temporal (10 millisecond) resolution remains unmatched by non-invasive methods and remains
the gold standard technique when considering revascularization (33). However, evaluation of
percentage diameter stenosis by means of invasive coronary angiography has limited value in
predicting future cardiac events and thus, novel promising methods are under development such as
3-dimensional coronary angiography in which the gantry is mechanically rotated thus providing a
multitude of X-ray projections during a single contrast injection (34).
Intravascular ultrasound (IVUS): IVUS is a minimally invasive imaging modality that uses
miniaturized crystals incorporated at the catheter tip to provide real-time, high-resolution, crosssectional images of the arterial wall and lumen with an axial resolution of about 150 µm and lateral
resolution of 300 µm (35). Lumen and vessel dimensions – plaque area, vessel area, plaque
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distribution, lesion length and remodeling index can be accurately predicted. In comparison to
angiography, IVUS provides more details on the lesion characteristics and can identify plaques
which are at a high risk of rupture and increasingly becoming the gold standard in trial evaluating
plaque progression or regression in the coronary arteries. However, the main limitation of IVUS
remains to be differentiation of plaque composition especially in areas of low echo reflectance
(fibrous tissue, fibro-fatty tissue, thrombus). Additional modifications to the current IVUS
techniques include backscatter IVUS (IB-IVUS) and virtual histology IVUS (VHIVUS) which uses
color coded maps of plaque composition to improve plaque compositional characterization (35).
Optical coherence tomography (OCT): Another invasive technique which has a unique highresolution imaging mode that uses low coherence, near infrared light for intravascular imaging of
the coronary arteries. With an excellent spatial resolution (10-20 µm; 10x IVUS) and histological
controls, OCT has been shown to be superior to IVUS in detecting important features of vulnerable
plaque components. Additionally, it enables quantification of macrophages within fibrous caps thus
allowing development of relationship between systemic inflammation and macrophage density in
fibrous tissues. Since blood significantly attenuates emitted infrared light, requirement of saline
flushes or balloon occlusion of the artery is necessary for adequate imaging. In addition, data
acquisition is time consuming and is confined to focal lesion exploration (35).
Calcium score (Non-invasive): Presence of coronary artery calcifications (CAC) confirms the
presence of atherosclerosis and it has been well established that visible CAC on invasive coronary
angiography is associated with risk of cardiovascular events. CAC scores are evaluated by the
widely-established electron-beam computed tomography (EBCT) (36) and more recently has been
performed with multiscale computed tomography (MSCT). Extensive calcification can be present
in the absence of luminal narrowing and thus, the specificity of CAC scores for obstructive CAD
is low (35).
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Computed tomography: Multi-detector CCTA is a useful first-line diagnostic test for appropriately
selected patients with symptoms of angina and a low-to-moderate probability of CAD and in this
context it has excellent negative predictive value thus, providing a remarkable mean to exclude
CAD when clinical diagnosis is doubtful (33). Currently, CCTS is not superior to clinical risk ±
CAC scores in asymptomatic patients nonetheless, it is an accurate test with good sensitivity to
detect anatomically significant CAD when compared with invasive angiography (37). With multislice CT, an improved approach of differentiating plaque composition has been established
however, this technique is associated with radiation exposure and the resolution also is inferior
compared to invasive imaging (35).
Magnetic resonance imaging: Currently, MRI can differentiate atherosclerotic tissue without
exposure to radiation using features such as chemical composition, water content, molecular motion
or diffusion. Good correlation has been identified between fibrous cap integrity on MRI and histopathological specimens. It is a very useful technique to evaluate plaque progression following lipidlowering therapy. However, plaque imaging of the coronary arteries with MRI remains challenging
since deep location, motion and respiratory artifacts, and small caliber vessels are difficult to
visualize (35).
Molecular imaging with nuclear techniques: Dedicated tracers enable nuclear imaging techniques
such as single photon emission tomography (SPECT) and positron emission tomography (PET)
target distinct mediators and regulators involved in the cascade of atherosclerosis. Feasibility of
tracing molecular markers of MMP release, Apoptosis and F18-flurordeoxyglucose (FDG) are
currently being explored for identification of vulnerable lesions (35).
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1.3.7 Clinical Intervention
For atherosclerotic lesions requiring intervention, three main procedures are commonly usedBalloon angioplasty alone or with Stent-implantation, Coronary artery bypass graft (CABG).
Coronary Artery Bypass Graft: For multi-vessel lesions, diabetes mellitus, severe ventricular
dysfunction patients, coronary arterial or vein graft is a suitable surgical procedure. Polymeric
grafts made from Dacron, polyester or polytetrafluoroethylene (PTFE) are available. Complications
associated with the surgical procedure make this as a high-risk option and typically is the end resort
for multi-lesion cases. In addition, problems such as donor-site morbidity, systemic prevalence of
atherosclerosis are common with natural graft procedures. With syndetic/polymeric grafts, material
biocompatibility issues mandate lifelong anti-thrombotic regime and hemodynamic differences at
the site of anastomosis can result in intimal hyperplastic response.
Angioplasty: This procedure involves compression of the atherosclerotic plaque to restore flow.
During this procedure, a catheter is inserted usually into the femoral artery with a deflated balloon
on a catheter tip. The most commonly used materials for manufacturing balloons are polyethylene
(PE) or polyethylene terephthalate (PET). Balloons are available in different diameters and length
depending upon the lesion site. At the lesion site, a balloon is inflated with saline typically to
pressures of about 5-15 atm. Mechanistically, balloon expands until the deployment forces equals
vessel wall circumferential force resulting in reopening of the blood vessel (38).
Stenting: A stent is a mesh-like scaffold that prevents the negative recoil of blood vessel after
angioplasty. The expansion of a stent to its yield strength ensures that the stent does not collapse.
Commonly used materials for stents include stainless steel, cobalt-chromium, platinum-titanium
alloys, nickel-titanium, tantalum alloys. In addition to providing a scaffold for prevention of
negative recoil, stents have also been designed to slowly release drugs to control neointimal
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hyperplasia. First-generation drug-eluting stents include Paclitaxel eluting stents (Taxus, PES) and
Sirolimus eluting stents (Cypher, SES). Paclitaxel cause microtubular arrest through
polymerization of alpha and beta-tubulin in the cytoskeleton. Paclitaxel causes the cell cycle arrest
at the G2/M phase of mitosis.
In contrast, sirolimus inhibits the mammalian target of rapamycin (mTOR) and thus causes cell
cycle arrest at the G1 phase. A common clinical problem with first-generation DES was the latestent thrombosis and inflammation in response to the thick polymer coating (39). Second generation
DES include Zotarolimus-eluting stent (Endeavor, ZES) and Everolimus-eluting stents (Xience V,
EES) and bio-degradable polymer coated biolimus-ES (40).
1.4 Restenosis:
The major complication associated with PCI is Restenosis or re-narrowing/collapse of the blood
vessel which eventually necessitates revascularization or need for another intervention. Binary
angiographic restenosis is defined as the re-narrowing of the vessel lumen to > 50% occlusion,
usually within 3-6 months after PCI. Clinical restenosis is characterized by recurrent angina
pectoris requiring target vessel revascularization (TVR) (41). Restenosis is a common problem
after balloon angioplasty with rates up to 50-60% (42). With advent of bare metal stents, the overall
rates of restenosis have drastically reduced owing to the success of stents in preventing negative
remodeling but still remain as high as 25-30 % with bare metal stents (BMS) and lower with drug
eluting stents (DES) (43). In spite of major advances in interventional cardiology, restenosis
remains a consistent clinical problem owing to in-stent restenosis. Even with drug-eluting stents,
in-stent restenosis has been reported clinically especially in complex lesions. This has been, in part,
explained by the late catch phenomenon where vascular smooth muscle cells re-initiate
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proliferation and phenotypic modulation after the initial burst release of the drug has been removed
from the site.
1.4.1 Pathophysiology
Fundamentally, restenosis is a maladaptive response of the coronary artery to the trauma induced
during PCI procedures and comprises of the characteristic wound healing responses – thrombosis,
inflammation, cellular proliferation and extracellular matrix production that together contribute to
post-procedural lumen loss over approximately 6 months (44). Lumen loss after balloon
angioplasty can be separated into 3 distinct stages – early loss associated with elastic recoil, late
loss due to negative remodeling and neointimal hyperplasia (45).
Elastic recoil is a dynamic and progressive phenomenon that occurs immediately following PCI
and results in an immediate lumen loss with clinical reports of up to 34% lumen loss 15 minutes
after angioplasty (46) and may even lead to a 50% loss in lumen gain post angioplasty (47). With
the advent of stent-implantation, lumen loss due to elastic recoil has been significantly reduced
albeit, there may be occurrence of sub-optimal lumen diameter primarily due to improper stentpositioning.
Immediately following angioplasty, fracture of the atherosclerotic plaque exposes the
thrombogenic contents of the plaque to the flowing blood thus, triggering platelet activation and
thrombosis. The barotrauma from a PCI also results in endothelial denudation/damage and results
in loss of antithrombotic factors (e.g. nitric oxide, prostacyclin and tissue plasminogen activator)
further contributing to platelet adhesion and aggregation (44). Platelets, upon activation, release
mitogens including thromboxane A2, serotonin and platelet-derived growth factors (PDGF) which
ultimately results in phenotypic modulation of vascular smooth muscle cells resulting in their
migration to the intimal region, proliferation and synthesis of extracellular matrix (43).
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Negative remodeling may also contribute the development of restenosis as replacement of
hyaluronic acid with collagen in the extracellular matrix is believed to result in scar tissue formation
(45).
With stent-implantation, elastic recoil is virtually eliminated and neointimal hyperplasia is the main
mechanism responsible for lumen narrowing and subsequently in the events leading up to in-stent
restenosis. Early phase of in-stent restenosis (ISR) immediately after intervention results in
relocation of the plaque, reorganization of thrombus and an acute inflammatory response where
thrombus formation seems to be as a consequence of endothelial disruption ultimately leading to
deposition of fibrin and platelets at the site of injury (48). Thus, an increased leukocyte trafficking
is evident at the stent location with their subsequent migration into the intimal layer. Corroborating
platelets, monocyte/macrophages and VSMCs results in an increased production of adhesion
molecules, cytokines, chemoattractants and growth factors ultimately leading to greater recruitment
of inflammatory cells from the circulation (49).
With the increasing use of DES, especially in complex lesions such as lesions in left main artery,
bifurcations, small vessel vein grafts, chronic total occlusions and diabetic patients, ISR rates of up
to 10% have been reported (50,51). The time frame to restenosis after DES may be longer as
compared to BMS due to the application of anti- proliferative drugs with repots of up to 12 months
(52). Various factors, like BMS, have been implicated in the development of ISR with DES
including diabetes, lesion length, vessel diameter, implantation factors. In addition to these, factors
such as resistance to antiproliferative drugs, hypersensitivity reactions to the polymer and metal,
circulating levels of MMPs, low wall-shear stress, polymer release kinetics have also been
demonstrated to contribute to ISR development (53). Further, different types of DES have also been
shown to affect the phenotype of VSMCs with synthetic phenotype more frequent with BMS and
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paclitaxel-eluting stents (PES), intermediate with Zotarolimus-eluting stent (ZES) and Sirolimuseluting stents (SES), contractile with tacrolimus- eluting stent (TES) (54).
1.4.2 Role of Endothelial Cells: Mechanical injury from coronary intervention leads to denudation
of the endothelium and subsequently leads to a sequel of events resulting in VSMC migration and
proliferation. Re-endothelialization is a critical step to completion of the wound healing response
to PCI-induced injury of the vessel wall. Endothelial dysfunction is commonly observed at sites of
regenerating endothelium resulting in reduced nitric oxide action. Studies with drugs that enhance
endothelium-derived relaxing factors or diminish endothelium derived contracting factor
production have been shown to control restenosis (55). Further, the extent of the denuded area is
also contributive to re-endothelialization and hence intimal hyperplasia as small denuded areas heal
more quickly (56).
1.4.3 Role of Platelets, Macrophages and VSMCs: Proliferation and migration of vascular smooth
muscle cells from the medial layer over time results in the formation of neointima. As described
previously, increased trafficking of inflammatory cells and platelets at the site of injury leads to an
increase in local concentration of growth factors and cytokines which stimulate phenotypic
modulation of VSMCs possibly due to degradation of the basement membrane via MMPs secreted
by macrophages.
1.4.4 Role of Hemodynamics: In stented vessels, low wall-shear stress has been inversely correlated
with neointimal thickening using 3D-reconstruction and finite element analysis (57,58). Further,
Wenetzel et al also showed similar results in 14 patients after stent implantations in coronary
arteries (59). VSMCs respond to shear stress variations such that low wall-shear stress contributes
to VSMC proliferation and hence neointimal formation whereas high shear shows an opposite
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effect (60). Further evidence exists in studies where reduced number of stent wires and strut
thickness have resulted in less of vessel area exposed to low shear stress (61).
1.4.5 Classification of Restenotic lesions
Based on the angiographic patterns observed clinically a well-established lesion classification
system exists for in-stent restenosis according to the geographic distribution of intimal hyperplasia
in reference to the implanted stent (62). Patterns predicted using this classification system is very
well accepted by the surgical community in predicting the long-term need for repeat
revascularization and pre-intervention ISR pattern serves as an independent predictor of future
target vessel failure/repeat revascularization with 19%, 35%, 50% and 98% for class I, II, III, IV
respectively (64).
i.

Class I (Focal ISR group) – Lesions are ≤ 10 mm in length and are positioned at the
unscaffolded segment (i.e. articulation gap), the body of stent, the proximal or distal
margin (but not both) or combination of these sites (multifocal ISR).

ii.

Class II (Diffuse intrastent) – Lesions are > 10mm in length and are confined to the
stent(s) without extending outside the margins of stent(s).

iii.

Class III (Diffuse-proliferative) – Lesions are > 10 mm in length and extend beyond
the margin(s) of the stent(s).

iv.

Class IV (Total occlusion) – Lesions have a flow grade of zero.

1.4.6 Predictors of Restenosis
Predictors for restenosis have been categorized as patient-related factors, vessel-related predictors
and procedure-related factors. Various patient-related factors including high serum levels of Creactive protein (CRP) & Interleukin-6 (IL-6), previous angioplasty. However, the most consistent
patient-related factor is the presence of Diabetes with a 30-50% increased risk of developing
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restenosis. Vessel-related factors such as vessel diameter and lesion length independently serve to
predict the incidence of in-stent restenosis with larger diameter/shorter lesions demonstrating
significantly lower restenosis rates (63). Finally, procedure-related factors such as stent-strut
thickness, stent fracture, stent length and minimum lumen diameter serve as significant clinical
predictors of restenosis (51). Thinner-struts are hemodynamically more favorable as compared to
thicker struts. With increase in stent length, rate of In-stent restenosis (ISR) have been reported to
be nearly double for stent lengths > 35 mm (64).
Introduction of drug-eluting stent has successfully reduced the overall rates of revascularization in
comparison to bare-metal stents however, routine angiographic surveillance 6 – 8 months after stent
implantation has revealed ISR rates of 30.1% 14.6% and 12.2 % for BMS, first-generation DES,
second-generation DES respectively (65). Despite significantly greater rates of revascularization
associated with BMS, these stents are still used clinically in cases where DES are not affordable or
where bleeding is a major risk-factor due to extensive anti-platelet therapy required with DES. ISR
with DES is on the rise primarily due to wide clinical acceptance of this technology. ISR rates can
range from 3-20% depending upon the type of DES used, lesion complexity, lesion location (66).
In general, it may take longer to develop ISR with DES primarily due to delayed onset of intimal
hyperplasia owing to phasing out of the bulk of drug beyond 6 months (52). Factors which serve to
be predictors in development of ISR with DES are similar to BMS – diabetes, lesion length, vessel
diameter, implantation factors. Novel factors such as resistance to antiproliferative drugs,
hypersensitive reactions to the polymeric layer and metallic ions, altered hemodynamics, release
kinetics have also been reported to contribute to ISR development (65,66). The main predictors for
developing ISR with DES are:
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a. Patient-specific: Higher rates of ISR have been reported in patients with comorbidities like
metal allergy, local hypersensitive reactions to drug or the polymer on DES, age, female
gender, diabetes mellitus, chronic kidney disease, multivessel coronary artery disease,
hypertension amongst other (67,68). Specifically, diabetes associated complications such
as hyperglycemia, insulin resistance and insulin administration alongside hypertension
have been consistently reported to risk-factors for developing ISR even with the use of
DES (69,70).
The two common class of drugs that are used for DES are cytostatic drugs like sirolimus
and its analogues – which fundamentally arrest progression of cell-cycle by causing
inhibition of the mammalian target for rapamycin (mTOR) complex and cytotoxic drugs
like paclitaxel – which specifically bind to the bet-tubulin subunit of microtubules
ultimately preventing microtubular depolymerization (71). Genetic mutations rendering
cellular-resistance to these drugs and thus, influencing the sensitivity to these drugs have
been reported (72,73).
Hypersensitive response to stents was initially observed with early BMS where 316L
stainless-steel stents were reported to cause these allergic reactions owing to release of
nickel and molybdenum ions from stents (74). These were eventually addressed by using
stents made of cobalt-chromium alloy which demonstrated significantly lower release of
nickel and molybdenum ions. With DES, there were three principle components have been
reported to potentially cause hypersensitivity reactions – metallic platform, polymer
coating and drug (75).

b. Lesion-specific: Lesion characteristics such as lesion length, smaller reference artery
diameter, ostial lesions, initial plaque burden, residual plaque after implantation and neo-
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atherosclerosis have been reported to negatively affect the outcomes of stent implantation.
Lesion are typically focal in nature for DES with the exception of diabetic patients which
present with more diffused type lesions (76).
c. Procedural-specific: Procedure-specific problems that may result in ISR with DES include
– stent undersizing, incomplete lesion coverage, stent under-expansion and malapposition.
Stent under-expansion results from poor expansion of stent during implantation and may
not be detected angiographically. Typically, higher calcification of the lesion or inability
to fully expand the balloon inside the stent are primary suspects which result in stent underexpansion. Clinically, excellent expansion as evidenced by ≥90% minimum lumen area in
comparison to the reference lumen area prevent clinical manifestation of stent underexpansion (77).

Malapposition is a condition where stent-struts are not completely apposed to the blood
vessel – there is clear space between the stent struts and arterial intima where blood can be
detected. This complications cannot be detected angiographically and typically occurs with
the usage of under-sized stents or in arteries that have significant tortuosity and fluctuations
of reference arterial lumen diameter within the treated segments and encourages
thrombosis (78).

Non-uniform drug distribution owing to local blood flow alterations, strut overlap and
polymer damage may result in neointimal growth in regions of low drug availability.
Computational models have demonstrated these factors to influence the local drug
distributions (79). Non-compliant lesions and difficult delivery may strip the polymeric
layer of the stent ultimately compromising drug-elution kinetics. Additional variability can
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stem from metal-to-artery ratio which commonly is different for different DESs. All of
these alone or in combination may result in focal areas within the stented segment with less
than optimal drug release eventually contribution to the development of ISR (80).

Barotrauma outside stented segment as a result of balloon dilation during stent deployment
has been reported to be the primary site of restenosis with sirolimus eluting stent placement
(81). These geometrical-miss were effectively reduced through different strategies - by
deploying a short balloon to pre-dilate the lesion site, using single stent long enough to
cover the entire lesion length, post-dilations within the stented regions using short, high
pressure balloons (66).

Neo-atherosclerosis is defined as the condition where atherosclerotic lesions have been
identified within the stented regions of the blood vessel. It has recently gained attention
due to its common prevalence with the use DES owing to incomplete endothelial healing
from delayed release of drug by the stent. Neoatheroslcerosis is a frequent finding in DES
and occurs earlier than in BMS and is suspected to be a pro-thrombotic factor in stented
regions. Investigations have reported incidence of neoatheroslcerosis to be significantly
greater in DES lesions (31%) as compared to BMS lesions (16%) with detection as early
as 420 days with DES in comparison to 2160 days with BMS (82).

1.5 Diabetes and Restenosis:
With a total economic burden of $245 billion in direct and indirect costs, diabetes is amongst the
leading cause of deaths in the US (83) and combined with cardiovascular disease, about 68% of
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deaths are related to complications of diabetes and CVD and patients afflicted with diabetes have
a 4 to 6-fold increased risk of developing cardiovascular disorders (84).
Pathophysiologically, diabetes can result due to autoimmune response to beta-pancreatic cells
which are responsible for secreting insulin (type 1); peripheral insulin resistance in skeletal and
adipose tissue (type 2); pregnancy induced (gestational); drug or chemical induced (anti-retroviral
therapy and second-generation anti-psychotic drugs). Out of these, the two most commonly
observed forms of diabetes are type 1 and 2 and represent almost the entire burden on healthcare
with type 2 diabetes accounting for about 90% cases (National diabetes fact sheet, CDC). T1D is
characterized by a prolonged autoimmune attack of pancreatic beta cells carried by autoreactive Tcells and these patients are unable to secrete insulin in response to a glucose load manifesting
hyperglycemia. Type 2 diabetic patients develop desensitization of insulin receptors ultimately
rendering peripheral insulin resistance. A direct consequence of insulin resistance is the
dysfunctional glucose transport across target cells and dysfunctional lipid metabolism.
Hyperglycemia, hyperinsulinemia, dyslipidemia are common clinical features of T2D patients and
as the disease progresses significant reduction in beta-cells functions conjoins to exacerbate insulin
resistance (85).
As mentioned in the previous section, diabetes remains to be the most consistent patient-specific
risk factor or predictor for developing ISR even in the DES era. Studies from early PCI procedures
on angioplasty in diabetics demonstrated restenosis rates to be almost twice as much as in nondiabetic patients (63% vs 36%). These observations were initially correlated to late vessel occlusion
however, even after adjusting for late vessel occlusion, diabetic patients still demonstrated greater
restenosis rates (86). Clinical trials comparing restenosis post BMS implantation between diabetic
and non-diabetic patients demonstrated higher rates of both angiographic restenosis (diameter
stenosis ≥ 50% determined angiographically) (87–90) and clinical restenosis (requiring target
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lesion revascularization) (88,91,92). Since restenosis post stent implantation is primarily due to
exaggerated neointimal hyperplasia, these investigations concluded diabetic patients to be
associated with greater neointimal proliferation and increased tissue remodeling (93). In fact
clinically diabetes mellitus is the only patient-specific risk factor equivalent to 15 years of
cardiovascular ageing (94).
First generation DES reduced the overall rates of restenosis when compared to BMS alone in all
patients including those afflicted with diabetes due to the cytostatic or cytotoxic drug release from
the platform however, emergence of stent thrombosis resulted in safety concerns especially late
onset after a majority of the drug has been released and high-risk patients. Clinical investigations
have indicated a favorable survival rate with BMS in diabetic patients as compared to firstgeneration sirolimus eluting stents with additional evidence indicating higher relevance of adverse
cardiac events (95,96).
Despite the advances in drug-eluting stent technology with second-generation DES, patients with
diabetes undergoing revascularization continue to have worse outcomes compared with nondiabetic
patients with studies demonstrating less pronounced clinical advantage of second generation drug
eluting stents, especially in insulin requiring diabetic patients (97). Restenotic lesions characterized
at 1 year post DES implantation by optical coherence tomography revealed thicker neointima in
case of diabetic patients with evidence of direct association with poorly managed blood glucose
levels (≥ 7% HbA1C levels) (98). Major clinical trials with DES in diabetic patients have been
summarized in table 1.
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Clinical Trial

Outcome
Increased cardiac events after PCI in diabetic

SYNTAX (Taxus stent) (99)
patients
FREEDOM (Taxus stent) (100)

CABG superior to PCI for diabetic patients
Paclitaxel-eluting stents increase In-stent late

SPIRIT V (Xience V vs TAXUS) (101)
loss in diabetic patients
EES vs PES resulted in no difference for
Pooled analysis of SPIRIT II, III, IV and

diabetic patients while EES led to decreased

COMPARE (Taxus vs Xience V EES) (102)

mortality, myocardial infarction, stent
thrombosis and TLR for non-diabetic patients
In-stent restenosis (%) was greater in diabetic

ENDEAVOR IV (103)

patients treated with Zotarolimus-eluting
stents
Higher rates of cardiac events, TLR, target

E-FIVE (104)

vessel failure and stent thrombosis in diabetic
patients at 1 year follow-up
Higher TLR rates in diabetic patients

NAPLES-DIABETES (105)

ultimately resulting in greater cardiac events
with Zotarolimus-eluting stents

Pooled analysis of International global

Insulin requiring patients had rates of target

RESOLUTE (ZES) program (106)

lesion revascularization (13.7%)

Table 1: Major clinical trials evaluating the performance of DES in diabetic patients (107)
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1.5.1 Contribution of Hyperglycemia
Various clinical studies have demonstrated the impact of poor glycemic control associated with
increased restenosis resulting in higher rates of target lesion revascularization. In addition to longterm glycemic management, clinical studies have also underscored the importance of maintaining
procedural glycemic control since pre-procedure hyperglycemia (> 128 mg/dL) resulted in 33.8%
target-vessel revascularizations at 9 month follow up (108,109). Further, the importance of
managing pre-procedure glycemic control was further demonstrated in patients who had good longterm glycemic control (HbA1C ≤ 7%) but had elevated pre-procedure glucose concentrations (> 128
mg/dL), as these patients had greater restenosis rates (110). Although the exact mechanisms of
these effects were never explored, hyperglycemia was successfully demonstrated to be associated
with restenotic lesion development and progression (111).

Hyperglycemia in general, has been shown to increase platelet activation and aggregation through
upregulation of PKC activity (112), direct osmotic effects (113) and through induction of nonenzymatic glycation of platelet surface proteins (113). Additional studies have indicated increased
expression of P-selectin and CD40 ligands by platelets under hyperglycemic conditions (114,115).
Evidence exists for activation and increased expression of pro-coagulant tissue factors by
endothelial cells though the NF-ΚB pathway via hyperglycemia induced advanced glycated-endproducts (AGE) and reactive oxygen species (ROS) (116). Hyperglycemia directly reduces tissue
plasminogen activator (t-PA) ultimately contributing to initiation and development of thrombus
(117). For vascular healing, endothelial progenitor cells are believed to play an important role in
re-endothelialization of damaged intimal layer post-injury with evidence of circulating EPCs being
captured for regeneration of the endothelial lining (58). Hyperglycemia has been shown to
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adversely affect this process since high-glucose (12.5 mM) resulted in cellular senescence of EPCs
and potentially induced apoptosis as well though the p38 MAPK pathway (118).

Neointimal progression is primarily driven by proliferation and migration of smooth muscle cells
ultimately leading to restenosis. In vitro investigations have demonstrated greater proliferation of
vascular smooth muscle cells under high-glucose through elevated basic fibroblastic growth factor
(bFGF) (119), elevated transforming growth factors alpha (TGF-α) (120), upregulation of
osteopontin release (121), increased polyol pathway flux (122), upregulation of protein kinase C
(123), direct increase in DNA (124), increased IGF-1 responsiveness resulting in enhanced
proliferation and migration (125), suppression of AMP activated protein kinase (AMPK) resulting
in activation of mammalian target of rapamycin (mTOR) (126,127), upregulation of MAPK,
PI3K/AKT and NFKB (128). Even in animal models of diabetes, hyperglycemia has been shown
to cause higher cell proliferation 3-days post arterial injury in comparison to controls (129). These
studies demonstrate the influence in hyperglycemia in regulating the intimal response.

1.5.2 Contribution of insulin administration and insulin resistance
In the United States alone, approximately 1 in 4 diabetic patients are treated with insulin and insulin
treated DM represents a higher-risk group of patients (130). These patients typically have
prolonged duration of diabetes that is difficult to control alongside greater than normal levels of
HbA1C. Insulin requiring patients additionally present additional complications – hypertension,
dyslipidemia and exogenous insulin administration has been shown to be a powerful cardiovascular
risk factor in patients with type 2 diabetes. (131). Kronmal et al reported measurements of fasting
serum insulin levels to be strongly correlated to developing coronary heart disease. In addition,
patients with higher levels of insulin (906 – 2400 pmol/L) were almost 6-fold likely of developing
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coronary complications (132). Although the exact mechanisms are not properly understood, poorer
outcomes are considered to be a multi-factorial problem where insulin is suggested to be proinflammatory and accelerate atherosclerosis (133), increase thrombogenesis (134), and impair
fibrinolysis (135). Circulating insulin levels in the body can vary due to multiple factors including
but not limited to age, glucose load, lifestyle, body mass index, insulin resistance, hyperglycemia,
pancreatic beta cell function etc. In healthy lean individuals circulating venous (or arterial) fasting
insulin concentrations are about 18 – 90 pmol/L (136) however, under diabetic conditions these
values can range from anywhere between 194 – 2000 pmol/L. These variations are primarily driven
by the glucose load and insulin concentration tend to be towards 2000 pmol/L after 1 hour of
glucose administration (137).

In the context of restenosis, multiple clinical trials have demonstrated insulin to be associated with
poorer outcomes after PCI procedures (previously summarized in table 1). These studies indicate
poorer outcomes of intervention especially in patients requiring external insulin administration. In
animal models of diabetes requiring insulin administration, greater neointimal response to balloon
injury (138) and stent implantation (139). Further, hyperinsulinemia has been reported to induce
proliferation of VSMCs in experimental models of diabetes (140,141). Insulin itself is considered
to be a weak mitogen but it is known to potentiate expression of platelet derived growth factor and
insulin-like growth factor (142,143). Insulin has also been shown to augment the influence of
PDGF and thus, promoting further stimulation (144).

Insulin resistance is a state in which peripheral tissues have decreased sensitivity to insulin
ultimately leading to increased circulating insulin levels to maintain normal glucose concentration.
Most patients affected by insulin resistance are also accompanied by central obesity, arterial
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hypertension, dyslipidemia and other cardiovascular risk factors. Presence of multiple of these
complications is clinically identified as metabolic syndrome. Insulin mediates its effects through
two distinct pathways – AKT/PKB for metabolic effects and Ras/Raf/MAP kinase for mitogenic
effects (145–147). A disturbance of the metabolic signal pathways via IRS/PI3K/AKT is present
in insulin resistance in type 2 diabetes whereas the mitogenic pathway of the insulin signal via
MAPK is not affected. Thus, with insulin resistance, a reduced cellular action of insulin is found
concerning the metabolic but not mitogenic effects of insulin (148). As diabetes progress, there is
significant loss in insulin secretion by beta cells and consequently, a loss of beta cells mass is also
observed (149).

Like skeletal muscle tissue and adipocytes, VSMCs are also sensitive to the metabolic effect of
insulin. Insulin has been shown to regulate glucose uptake and metabolism in VSMCs thus,
establishing them as insulin sensitive (150,151).

Glucose transporters (GLUT4), which are

primarily responsible for transport of glucose across insulin-sensitive tissues have been detected in
the vasculature (152). Upon stimulation with insulin, vesicles fuse with plasma membrane via
exocytosis and consequently result in increased cell-surface expression of glucose transporter. This
increase results in proportional increase in glucose transport across cells to maintain glucose
homeostasis. This mechanisms involves a tyrosine phosphorylation cascaded that is triggered by
the binding of insulin to IRS and includes activation of PI3K/AKT (153). Figure 4 displays the very
basic pathway depicting the mitogenic and metabolic actions of insulin on muscle cells.
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Figure 3: Metabolic and mitogenic actions of insulin on smooth muscle cells

1.6 Hypertension and Restenosis
Systemic arterial hypertension is the condition of persistent, non-physiological elevation of
systemic blood pressure (BP). Current clinical standards dictate resting systolic blood-pressure to
(SBP) ≥ 140 mmHg whereas diastolic pressure to be ≥ 90 mmHg (154). The exact causal factors
of hypertension are not entirely clear however, in general genetic, environmental and behavioral
factors are known to influence development of hypertension which in the long run influences
cardiovascular disease since hypertension is also amongst major causal risk factors for CVD –
including heart disease, vascular disease and stroke, and renal disease. About 30.9% of the US
population are affected by hypertension (155). Although, blood-pressure elevation from the normal
values of 120/80 mmHg (SBP/DBP) is considered to hypertension, there are generally four
different categories of hypertension (154).
a. Normal (SBP < 120 mmHg and DBP < 80 mmHg)
b. Prehypertension (SBP 120-139 mmHg or DBP 80-89 mmHg
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c. Stage 1 hypertension (SBP 140-159 or DBP 90-99 mmHg
d. Stage 2 hypertension (SBP ≥ 160 or DBP ≥ 100 mmHg

Primary hypertension accounts for the majority (>90%) of cases of human hypertension which
stems from a complex interaction of a multitude of factors including but not limited to increased
sympathetic nervous system activity, psychological stress, high sodium intake, inappropriate reninangiotensin secretion, deficiency of vasodilator peptides, nitric oxide, diabetes mellitus, insulin
resistance, obesity, altered ion transport among others.

Clinically, hypertension is also a patient-specific risk associated with poorer prognosis of PCI with
hypertensive patients affected by greater restenosis (156). In addition, high SBP levels both in
clinical (peri-procedural) and invasive (intra-procedural) measurements have been associated with
greater risk of restenosis for single vessel disease (69). Chronic hypertension in experimental
animals and in human subjects has been well documented to result significant wall thickening
(157), hypertrophy of medial smooth muscle cells and increased connective tissue content (158–
160). A direct consequence of elevated blood pressure on the vessel wall is elevated circumferential
strain which may increase by as much has 30% thus, resulting in altered VSMC proliferation,
hypertrophy and deposition of extracellular matrix – particularly collagen (161,162).

1.7 Cellular-response to drugs from stents
DES are essentially biomaterials capable of delivering drugs locally and in a controlled manner to
eradicate the increased neointimal proliferation owing stent implantation, which is the primary
cause of restenosis. As stents are placed within the blood vessel – it results in deep, local and
prolonged injuries to the blood vessel layers and denudation of the endothelial layer. Sullivan et al
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have demonstrated the extent of injury to the internal elastic lamina to be correlated to neointimal
proliferation where greater damage was associated with poorer outcome (163). The barotrauma
results in release of growth factors which dictate VSMCs to enter G1/S phase of cell-cycle thereby
encouraging migration and proliferation into the intima (164). Lack of endothelium further
encourages an inflammatory response subsequently culminating in greater proliferative response
of VSMCs. Thus, activation of VSMCs served to be the therapeutic target for DES. Essentially,
two classes of drug have been commonly used for DES – Cytostatic (Sirolimus and analogues) and
Cytotoxic (Paclitaxel). The most common DES used clinically are summarized in table 2 (164).
Table 2: Major DES used clinically
Stent

Technology/Polymer coating

Limitations

Non-erodible poly(ethylene-co-vinyl

•

Late stent-thrombosis

acetate) and poly(n-butyl methacrylate)

•

Hypersensitivity

carrier : 67% polymer and 33% drug

•

Inflammatory

Triblock polymer – TransluteTM using a

•

In-stent thrombosis

TAXUS

poly(styrene-b-isobutylene-b-styrene)

•

Hampers re-

(Paclitaxel)

tetra polymer

CYPHER
(Sirolimus)

endothelialization
•

Hypersensitivity

Biocompatible phosphorylcholine

•

Diabetes

Endeavor

coating on Co-Cr alloy base.

•

Small vessel

(Zotarolimus)

Zotarolimus – extremely lipophilic and

•

Dual anti-platelet

is not solubilized with blood flow

therapy

Xience VTM

Better stent platform – high flexibility

•

Diabetes

(Everolimus)

and deliverability, better compliance.

•

Small vessel
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More polar nature reduces the tissue

•

Cost

concentration of the drug. Uses a

•

Dual anti-platelet

hydrophilic poly(vinylidene fluoride-

therapy

co-hexafluoropropylene) which has
improved compatibility at the adluminal
surface

Paclitaxel (taxanes) was initially approved by the FDA for its anti-neoplastic use for ovarian cancer
treatment in 1992. Currently, it is still used for intravenous treatment of lung, breast and ovarian
cancer (164). Paclitaxel promotes polymerization of the α and β subunits of tubulin by reversibly
and specifically binding the β subunit of tubulin. As a result of polymerization, paclitaxel stabilizes
microtubules which are required for G2 transition into the M phase of the cell cycle in VSMCs
(figure 4). The drug successfully blocks cellular proliferation at the G2/M phase. Due to its highly
lipophilic nature, paclitaxel is easily taken up in the vasculature. Paclitaxel leads to an almost
complete growth inhibition within a dose range of 1.0 – 10.0 mmol/L even with short duration of
exposure (~ 20 minutes)(165).

Sirolimus was discovered in soil samples as a naturally occurring product in Streptomyces
hygroscopicus. It is a 31-memebr macrocyclic lactone that was initially approved by the FDA as
an immunosuppressant agent (166). Sirolimus and its analogues (Zotarolimus and Everolimus)
inhibit SMC proliferation by binding the cytosolic FK-binding protein 12 (FKBP12). This prevents
activation of the mammalian target of rapamycin (mTOR) and ultimately leads to interruption of
the cell-cycle progression in the G1/S phase (167). The mTOR is a large evolutionarily conserved

37

member of the phosphatidylinositol kinase (PIK) related kinase family that regulated protein
translation, cell-cycle progression and cell-proliferation.

Tubular
polymerization

Paclitaxel

Cyclin B

CDK1

G2 phase

M phase

CDK1
Cyclin A

G0

Cell Cycle

CDK4/6
Cyclin D

S phase

G1 phase

CDK2

CDK2

Cyclin A

p27kip/cip

Cyclin E

Sirolimus
Figure 4: Schematic representation of cell-cycle targets of paclitaxel and sirolimus.

Within the cell-cycle (figure 5), cyclin-dependent kinase (CDK) activity is reduced ultimately
reducing phosphorylation of the retinoblastoma protein. CDK inhibitors p27kip1 mediates sirolimus’
anti-proliferative and anti-migratory properties in smooth muscle cells (168). In response to growth
factors or mitogens, p27kip1 levels decrease thus allowing higher activity of CDKs ultimately
manifesting into progression within the cell-cycle. During mitogen deprivation, p27kip1 levels
increase resulting in reduced activity of CDKs which prevents progression within the cell-cycle
(169). Thus, sirolimus inhibits mitogen-induce downregulation of p27kip1 in addition to inhibition
of p70S6k phosphorylation (170) and activity, phosphorylation of the eukaryotic translation
initiation factor 4E-binding protein (171).
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Figure 5: Schematic representation of mechanism of sirolimus induced cell-cycle arrest.

Sirolimus has been shown to demonstrate anti-proliferative effects on VSMCs in a dose-dependent
manner in the range of 0.1 – 100 ng/mL. These effects were explored in both porcine and human
venous smooth muscle cells (172). With VSMC migration, concentrations > 0.1 ng/mL have been
reported to be significantly effective in controlling migration. In addition, 50 ng/mL sirolimus was
shown to be effective in controlling neointimal hyperplasia in ex-vivo models although statistical
significance was not achieved (173). Wessely et al measured sirolimus concentration in blood after
deployment of drug-eluting stents with a custom coating system and reported concentrations in the
range of 10-30 µg/L (or ng/mL). This range also captured the release profile of Sirolimus-eluting
stent as well, which had very similar release kinetics as the custom system. In addition, both the
custom system and SES resulted in similar neointimal outcome after 30 days indicating the custom
system and SES to be very similar and following similar kinetics (174).
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Summary
Pathophysiology of In-stent restenosis and Contribution of VSMCs: Restenosis is a maladaptive
response of the blood vessel to the trauma induced by PCI procedures with the sequence of eventsthrombosis, inflammation, VSMC proliferation and migration and extracellular matrix production
(175). In-stent restenosis is primarily driven by exaggerated neointimal hyperplasia, since the
metallic scaffold prevents negative recoil of the blood vessel, as observed in case of stand-alone
angioplasty (2). In the early phase, immediately after an intervention, relocation of plaque,
reorganization of thrombus and an acute inflammatory response is observed which, although
resolves in a few days to week, results in the onset of the late phase where phenotypic modulation
of VSMCs leads to their migration into the intima and subsequent proliferation and synthesize
copious amounts of extracellular matrix thus, increasing the bulk of the neointimal tissue (18).

The vessel trauma caused during implantation of a stent leads to denudation of the endothelial
lining followed by delayed healing, which in case of drug eluting stent, may take up to 48 months
for complete re-endothelialization (3,4). Under these conditions, VSMCs may be directly subjected
to shear forces from blood flow which are normally experienced by endothelial cells. Further,
neointimal thickness in stented blood vessels has been correlated with areas of flow separation,
zones of recirculation or point of flow-reattachment where average wall shear stress can be as low
as < 5 dynes.cm -2 (7). In case diabetic patients, it is further complicated by endothelial dysfunction
which may further delay intimal healing in addition to being a consistent risk factor for developing
atherosclerosis and additional ‘pro-restenotic’ factors (e.g. hyperglycemia, hyperinsulinemia,
insulin resistance, hypertension etc.) working concomitantly with altered hemodynamics, which
may contribute to exaggerated neointimal hyperplasia observed commonly in this patient
population.
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Mechanical forces and VSMC-response: In normal and healthy blood vessels, vascular cells are
subjected to cyclic strain due to pulsatile nature of blood flow in addition to wall shear stress, owing
to the viscosity of blood. The typical range for cyclic strain has been reported to 1-2 e6 dynes/cm2
(20) along with typical mean arterial shear stresses from 6-40 dynes.cm-2 depending upon the
anatomical location (21). Application of physiological levels of cyclic strain (≤10%) have been
shown to promote quiescence and prevent proliferation of VSMCs (22), whereas higher strain
levels may promote dedifferentiation and proliferation of these cells and may even cause apoptosis
(23) as compared to static cultures, thus substantiating the relevance of cyclic-strain application in
mechanosensitive cells.

Stent implantation leads to variations in arterials geometry thus resulting in areas of localized
turbulence which, in turn, can result in creation of zones of separation/areas stagnation which are
associated sub-optimal wall shear stress, typically less than < 5 dynes/cm2 (7). In addition, preclinical investigations with stent-implantation in animal models have previously demonstrated
areas of low and oscillatory wall shear stress to be correlated with neointimal thickening within
stented vessels (24). These observations are consistent with 3-dimensional mesh analysis studies in
human arterial post-angioplasty analysis (25). Further, contribution of local wall shear stress postPCI can be appreciated from the radical change in stent-strut design with older stents with thicker
and squared-struts were found to be inferior to newer stents with thinner and rounded struts. At a
cellular level, VSMCs subjected to physiological shear stresses have been shown to reduce
proliferation and phenotypic modulation (26) whereas low wall shear stress promoting smooth
muscle cell proliferation (27).
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These clinical and pre-clinical observations demonstrate the versatility of VSMC response thus
underscoring the need to evaluate cellular-response under clinically relevant mechanical loading
conditions. In the currently proposed research project, a previously designed and characterized
vascular simulator was employed (28) which is capable of concomitant application of
physiologically relevant cyclic strain and low wall-shear stress, typifying dynamic loading on
vascular cells post stent implantation in patients.

In vitro response-evaluation modeling can be extremely beneficial in determining the exact
mechanism involved and developing causal relationship between stimulus and response, primarily
due to lack of precise experimental control with animal models and impracticality of such
investigations in humans. However, in vitro investigations pertinent to neointimal hyperplasia and
In-stent restenosis are currently limited to studies focused towards evaluating drug-toxicity and
efficacy under static unloaded conditions which fail to recapture the mechanically-dynamic
environment observed clinically.
Although, in vitro investigations with dynamic loading have contributed significantly to the current
understanding of VSMC-response under different regimes, prior investigations have failed to
incorporate disease-related biochemical and biomechanical modifications especially those
associated with diabetic and hypertensive patients. Patient-specific complications continue to
impact the prognosis of DES implantation even with second-generation stents.
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Chapter 2: Research Overview
2.1 Research aims and rationale:
Diabetes remains as the prime patient-specific risk factor in case of Balloon Angioplasty (BA) (8),
Bare-metal stent (BMS) (9,11) and Drug-eluting stent implantation (DES) (13,58) with clinical
evidence of exaggerated neointimal hyperplasia for all interventional procedures, as compared to
the non-diabetic patient population. Consistent with BMS implantation (14), insulin-treated
diabetic patients have been associated with greater rate of target lesion failure as compared to noninsulin treated diabetes with Resolute-Zotarolimus eluting stent (R-ZES), which is the only FDAapproved DES for diabetic patients, thus indicating the contribution of insulin to the development
of restenosis despite the similar rate of stent-thrombosis (15).

In pre-clinical investigations, diabetes has been demonstrated to positively correlate with
neointimal thickness (16,176). In support of the clinical observations in diabetic patients requiring
insulin administration, rat models of diabetes have been demonstrated to exhibit greater neointimal
hyperplasia post balloon angioplasty, upon insulin administration (4). A multitude of diabetes
specific complications have been linked to an exaggerated NIH and despite various clinical and
pre-clinical investigations indicating contribution of diabetes-associated complications to
neointimal development post-PCI, current interventional approaches do not account for variations
in cellular-response associated with diabetes primarily due to lack of knowledge on exact
mechanisms in these complicated conditions. This gap in knowledge can be associated to lack of
precise variable-control in animal models and impracticality of investigating causal relations in
human subjects. Thus, in vitro studies can be utilized to abridge this knowledge gap and further the
current understanding of ISR in diabetic patients. This dissertation project proposes a in vitro
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cellular-response specific test model which has successfully combined implant-associated altered
mechanical forces with patient-specific complications through the following aims:

Aim 1: Development and characterization of diabetic cellular-response evaluation model for instent restenosis
Hypothesis: Insulin administration will promote proliferation and dedifferentiation of chronic
high-glucose acclimated RASMC under physiologically relevant circumferential stretch with low
wall-shear stress and this effect will be enhanced in case of partially induced insulin administration.

Rationale: Insulin is commonly administered under clinical settings to achieve normoglycemia in
diabetic patients. Since diabetic patients requiring insulin-mediated glycemic control have
significantly greater rates of revascularization post PCI, insulin administration and partial insulin
resistance may contribute to the poorer response to PCI procedures. As neointimal hyperplasia is
primarily driven by VSMC proliferation and phenotypic modulation, subjecting VSMC to dynamic
loading conditions under diabetes related insulin administration and selective insulin resistance will
capture the clinically relevant response more accurately. Blocking the phosphatidylinositol-3kinase (PI3K) enzyme with wortmannin is a known approach to hamper glucose transport across
cells, a cellular complication associated with insulin resistance. Thus, by blocking the “metabolic”
arm of insulin receptor mediated glucose transport this approach captures partial insulin resistance.

Aim 2: Development and characterization of hypertensive-diabetic cellular-response evaluation
model for in-stent restenosis
Hypothesis: The application of elevated mechanical strain with low-shear stress will result in
greater dedifferentiation of RASMCs and insulin administration will augment this effect. In
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addition, due to a proliferative effect of these factors, equimolar concentration of sirolimus will
result in poor regulation of VSMC phenotype.

Rationale: A vast majority of diabetic patients are also afflicted with hypertension with substantial
clinical evidence indicating high blood pressure leading to greater restenosis. Elevated blood
pressure results in greater circumferential strain exerted on the vascular wall, and in case of denuded
endothelium, directly on VSMCs. Higher than normal circumferential strain has been shown to
promote VSMC proliferation and migration (177) thus, hypertension-associated cyclic strain
should corroborate in phenotypic modulation of VSMCs during partially induced insulin resistance
and insulin administration.

2.2Research significance
2.2.1 In vitro cell-response testing platform: The current standard of testing cellular response to
clinical complications is primarily limited to static cultures which not only fails to capture the
relevant response but also does not represent the clinical conditions. Mechanosensitive cells such
as vascular smooth muscle cells (VSMC) are very responsive to subtle changes in blood vessel
mechanics and hemodynamic alterations resulting from percutaneous coronary intervention (PCI)
procedures such as balloon angioplasty and stent-implantation. The mechanical injury from these
interventional procedures significantly affects local cellular responses such that VSMCs, which
physiologically are exposed to circumferential strain are now, in addition, directly exposed to wall
shear stress from blood flow. Various clinical and pre-clinical studies have established significant
evidence demonstrating the contribution of these mechanical cues in VSMC-response (178).
However, incorporation of these mechanical forces within basic cell culture investigations still
remains uncommon and a vast majority of basic science studies designed to explore causal
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mechanisms, are still confined to static-unloaded culturing approaches thus, fail to combine
disease-associated complications in vitro. Consequently, a major drawback of these investigations
is the lack of correlation of cellular-response in cell culture studies with pre-clinical or clinical
observations. Our approach successfully incorporates clinically relevant cyclic strain and stentassociated low wall-shear stress at an in vitro level representing clinically relevant cellular response
more accurately.

2.2.2 Combining patient-related complications with in-vitro culturing approach: Diabetes has been
a consistent patient-specific risk factor for developing neointimal hyperplasia (NIH) ultimately
leading to restenosis for all coronary interventions. Even in the drug eluting stent era, diabetic
patients show more incidence of restenosis as an outcome of endovascular procedures. Current in
vitro cell-response evaluating approaches to mitigate restenosis do utilize VSMCs isolated from
various diabetic sources (179) however, these approaches fail to include relevant mechanical
loading. Further, there is significant variation in cellular-response between different diabetic
models alongside lack of correlation with clinical response (138)(176)(129). In addition, the current
test model successfully subjects VSMCs to hypertension-related elevated circumferential strain
while maintain diabetes-associated insulin administration.

Our approach of combining diabetes-related biochemical complications such as chronic highglucose, insulin administration and selective insulin-resistance with stent-related hemodynamic
alterations uniquely combines patient related factors and clinically relevant mechanical forces in
vitro. In addition to diabetes, patient afflicted with hypertension are also at a higher risk with
clinical reports of poorer outcomes of PCI in patients with diabetes and hypertension (180). Our
approach of applying hypertension-related cyclic strain under diabetes-related insulin resistance
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and insulin administration will capture the clinical response of such patients more accurately, as
compared to static cultures. All the factors specified: diabetes, hypertension and hemodynamic
alterations independently affect VSMC-response and drug efficacy however, a combination
approach where all these are tested together has not been conducted yet. Such combinations are not
feasible in animal models owing to lack of proper experimental control for cause and effect in
addition to impracticality of conducting these investigations in humans.

2.2.3 Testing drug-efficacy under pathophysiological conditions: Currently, in vitro studies
contribute primarily to evaluating the toxicity of drugs intended to control restenosis however, with
our modeling approach, drug efficacy in controlling VSMC proliferation and phenotypic
modulation was tested under diabetes-hypertensive conditions thus, providing a more clinically
accurate environment at an in vitro level. This diabetic-hypertensive cellular-response evaluation
model may be utilized to investigate cellular and molecular mechanisms that may be contributive
to restenosis in a diabetic-hypertensive environment and can also be utilized for testing and trial of
novel therapeutic targets and drugs aimed at reducing restenosis in these patients before evaluating
them in animal models. Future exploration of pathways and therapeutic targets with this model will
be extremely useful in reducing the lack of correlation between cellular-response and clinical
observation with improved clinical efficacy of anti-restenotic drugs.

2.3 Research Innovation
2.3.1 Correlation to Clinical Relevance: Our current approach combines two of the fundamental
contributors of in-stent restenosis namely 1) altered hemodynamics due to stent design and 2)
patient-specific biochemical complications such selective insulin-resistance alongside insulin
administration. This approach is unique since it incorporates diabetes-associated cellular response

47

with the physiologically relevant mechanical forces and thus captures the clinical condition of
diabetic patients, with endovascular stents, in vitro more accurately. Further, increased cyclic strain
characteristically associated with elevated blood pressure was employed to represent the VSMCresponse more accurately for diabetic patients with hypertension thus, simulating coexistent
patient-specific conditions under clinically relevant conditions. This methodology combines
implant related mechanical forces with patient specific complications of diabetes and hypertension
at an in vitro level which continue to be the patient cohort majorly affected by In-Stent Restenosis
(ISR), even in the second-generation drug eluting stent era.

2.3.1 In vitro modeling of diabetes and hypertension associated complications: Wortmannin has
previously been employed for evaluating the contribution of phosphatidylinositol-3-kinase enzyme
in various cell and molecular pathways, PI3K/Akt inhibitory approach was utilized in order to
induce selective insulin-resistance since this pathway has been demonstrated to hamper insulinmediated glucose transport across cellular membrane. The phenomenon of insufficient insulinmediated glucose transport is clinically defined as the peripheral insulin resistance in which fat,
liver and muscular cells are unable transport and eventually metabolize glucose from the circulation
ultimately leading to hyperglycemia, hyperinsulinemia and elevated triglyceride levels (94). In
accordance with pathophysiology of peripheral insulin resistance, we attempted to block the
PI3K/Akt pathway in order to partially mimic these clinically relevant conditions at cellular levels
and thus have employed the approach of partial insulin resistance.
Insulin administration is a commonly employed strategy to ensure euglycemia in diabetic patients
and since substantial clinical evidence exists for higher rate of target lesion/vessel revascularization
in diabetic patients requiring insulin and for the development of an in vitro diabetic model, VSMCs
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were subjected to 10 ng/mL insulin during induction of quiescence and mechanical loading to
recapitulate the clinical scenario.
A direct consequence of hypertension is elevated blood pressure which ultimately exerts greater
force on the vessel-wall. In order to represent these conditions in vitro, our unique model
incorporated higher than normal circumferential strain (~15%) with low wall-shear stress with or
without insulin administration. Thus, providing a novel platform which combines the corroborating
effects of diabetes and hypertension with stent-specific hemodynamic alterations to a certain
degree, in order to provide a novel in vitro testing platform for cellular response evaluation under
these patients-associated conditions.
2.3.2 Use of model for evaluating drug efficacy: As an application of In vitro diabetic-hypertensive
model, cells were treated with 10 ng/mL sirolimus in the final phase. This was primarily performed
to evaluate if diabetes or hypertension associated complications incorporated into the model
influenced the efficacy of sirolimus in controlling proliferation and phenotypic modulation of
VSMCs. Thus, providing a clinically relevant approach of drug-testing under patient-specific
conditions in vitro.
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Chapter 3: “Development and characterization of diabetic cellular-response evaluation
model for in-stent restenosis”
Purpose: The current study explores the different treatments incorporated to capture the effect of
insulin administration and insulin-resistance on chronic high-glucose acclimated rat aortic smooth
muscle cell under dynamic loading. The aim of this study is to develop an in vitro cell culture
diabetic model that captures the clinically relevant cellular response in diabetic patients within
stented vascular regions afflicted with poor glycemic management requiring insulin administration.
Method: Passage 4 rat aortic smooth muscle cells (SMC) acclimated to chronic high-glucose (25
mM D-Glucose media, 3-4 weeks) were seeded on type I collagen coated silicon membranes and
subsequently subjected to 0-7% circumferential strain with low wall-shear stress (0.3 dynes/cm2)
in contact with wortmannin (100 nM, 84 hours), insulin (10 ng/mL, 48 hours) or a combination of
both to represent selective-insulin resistance, insulin administration, or combination respectively.
Treatments were evaluated by comparing cell-cycle distribution, apoptosis, estimation of cellular
hypertrophy, αSM actin, SM22α, p-AKT and p-ERK ½ expression.
Results: Combined application of circumferential strain and low wall-shear stress resulted in
greater proliferation and phenotypic modulation of chronic high-glucose acclimated SMC during
insulin administration compared to controls. A greater percentage of cells in the S (p < 0.0001) and
G2/M phase (p < 0.0001) of the cell cycle, reduced apoptosis (p < 0.0001) indicating greater cell
survival, greater cell hypertrophy estimated by higher cell-area (p < 0.0001) and lower aspect ratio
(p < 0.0001), reduced expression of contractile-phenotype associated markers -αSM actin (p <
0.0001), SM22α (p < 0.0001), higher expression of proliferation associated p-ERK ½ (p < 0.0001)
were observed in comparison to control. These results indicate that insulin administration
demonstrates a corroborating effect in conditions of poor glycemic control under dynamic
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mechanical loading. Wortmannin administration did not result in significant differences of the
cellular response despite resulting in a significantly reduced expression of p-AKT (p < 0.0001)
whereas insulin-wortmannin combination resulted in similar proliferation and phenotypic
modulation as insulin alone.
Conclusion: Our experimental approach successfully integrates mechanical forces observed in a
stented blood vessel with diabetic patient-related conditions such as chronic high glucose with
insulin administration, in vitro. Cellular-response under these conditions has not been performed
previously despite clinical relevancy and demonstrates the need to model cellular behavior under
disease-associated conditions to further improve prognosis of percutaneous interventional
approaches. Results from the current investigation demonstrate a differential cellular-response
under diabetes associated insulin administration which is significantly augmented by clinically
relevant mechanical loading. Future investigations should focus on exploring the precise
mechanisms such that it can be incorporated as a therapeutic target. Additional patient-specific
complications can also be combined with diabetes-associated conditions to further current
understanding of VSMC-response under complex conditions.
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3.1: Introduction:
Patients afflicted with diabetes and requiring insulin therapy represent a high-risk cohort for
restenosis, with increased rates of target vessel failure after coronary revascularization even with
second generation drug-eluting stents (70). Increased risk of restenosis is attributable to
exaggerated intimal hyperplasia ultimately necessitating subsequent target lesion revascularization.
In addition, percutaneous interventional procedures including angioplasty and stent implantation
result in vascular barotrauma which ultimately leads to endothelial denudation and exposes
underlying vascular smooth muscle cells to normally unseen shear forces in addition to
physiological circumferential strain (178).
Physiologically, VSMCs experience circumferential stress due to vessel-distension associated with
blood pressure (≤ 10%) which has been demonstrated to promote a contractile phenotype of
VSMCs in contrast to high strain, which in turn has been reported to promote proliferation and dedifferentiation of VSMCs (181–184). In addition, direct shear forces from blood flow have also
been reported to influence VSMC phenotype with physiologically relevant shear stress reducing
proliferation and promoting contractile phenotype (185,186) while low-wall shear stress leading to
proliferation, migration and dedifferentiation (61,187). An altered cellular response in presence of
mechanical forces further emphasizes the mechanosensitive nature of VSMCs and thus,
necessitates mechanical loading of these cells to better capture their physiologically relevant response.
Insulin administration and insulin-resistance have been previously reported to exert a proproliferative effect on vascular smooth muscle cells, with insulin-effects in a concentration
dependent manner (141,188–190). Additional investigations have reported greater neointimal
hyperplasia post balloon-injury and stent-implantation in pre-clinical models of diabetes (139,191).
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However, effects of these diabetes-related complications have not been explored under
physiologically-relevant circumferential strain and stent-associated low wall-shear stress. Under
diabetes associated chronic high-glucose conditions, we have previously demonstrated the effect
of chronic high glucose on phenotypic modulation of rat aortic smooth muscle cells (RASMCs)
during dynamic loading (192).

In the current study, additional complications of insulin

administration and insulin-resistance, both of which are clinically relevant for diabetic patients
undergoing PCI, are investigated.
In order to combine these patient-specific complications with dynamic loading, we subjected
RASMCs to physiologically relevant insulin administration and induced insulin-resistance with
circumferential strain and low wall shear stress. Current experimental approach attempts to
conceptualize an in vitro diabetic model which successfully captures VSMC-response under insulin
administration and insulin-resistance conditions more accurately in comparison to conventional
static/unloaded conditions. We hypothesize that insulin administration will promote chronic-high
glucose acclimated RASMC proliferation and dedifferentiation and this effect will be enhanced in
case of partially induced insulin resistance. In future, this model can be utilized to explore the
efficacy of novel anti-restenotic drugs in vitro and can also be combined with additional patientspecific complications to capture clinically relevant cellular-response more accurately.

3.2: Materials and Methods:
3.2a. Isolation of rat aortic smooth muscle cells: Rat aortas were harvested from 9-10 weeks old
female Sprague-DawleyTM rats using a modified version of previously published protocol approved
(193). The modified version was approved by Clemson University Institutional Animal Care and
Use Committee (IACUC). Briefly, aorta isolated from rat, was transferred back to the laboratory
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and immediately rinsed with 1x sterile Dulbecco’s phosphate buffered solution (DPBS; Cellergo,
21-031-CV) at 37 0C for 1-2 minutes in order to remove blood clots and any unwanted tissue. Aorta
were subsequently treated with Collagenase type-II (300U/mL, Worthington 4176) in sterile
Dulbecco’s modified essential medium (DMEM with 25 mM D-Glucose; Corning 10-013-CM) for
12-15 minutes to enable enzymatic degradation of the adventitial layer. Subsequently, using
straight and angular forceps, tears in the adventitial layer were created to facilitate its easy removal.
After successfully removing the adventitial layer, aorta was split open along its longitudinal axis
thus, allowing easy scraping on the luminal side to remove the endothelial monolayer. Multiple 1x
DPBS rinses were performed to ensure removal of any loose cells and tissue after which, aorta was
chopped into small sections (about 1mm2) and subjected to another enzymatic digestion containing
type I collagenase - 10mg/mL, elastase (10 U/mL, Worthington 2292) treatment for 3-4 hours under
gentle shaking conditions at 37 0C thus allowing complete dissolution of the extracellular matrix of
the medial layer. At the end of enzymatic digestions, the suspension was centrifuged and cells were
transferred to T-25 flasks in DMEM (containing 25 mM D-Glucose) supplemented with 10% fetal
bovine

serum

(FBS;

Corning

35-010-CV)

and

1%

Antibiotic-Antimycotic

agent

(Penicillin/Streptomycin; Cellgro 30-004-CI). The primary cell line was incubated for about a week
before passaging and subsequent passaging was performed every two weeks until passage 4. Cells
were recruited at passage 4 for all experiments, in order to remove any passage-associated
variability.

3.2b. Preparation of silicone membranes and Cell seeding: For this work, two baseplates were used
providing a total sample size of 6 test specimens per experiment. Biomedical-grade silicone
membrane of 0.015-inch thickness (0.15” NRV G/G 40D, Specialty Manufacturing Inc., MI) were
cut to fit the custom cell-culture assembly (Figure 6a) which were coated with type 1 collagen using
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Teflon ring (2.75 cm2 inner cross-sectional area and 1.2 cm height) centered on the silicone surface
exactly above the loading post (Figure 6b). To minimize friction between the loading post and the
silicone membrane, 0.2 ml of silicone lubricant (Loctite, 51360) was distributed evenly on the
loading-post under aseptic conditions.

Figure 6 A: Components of the custom cell-culture assembly with outer ring, inner ring,
silicone sheet (l-r); B: Cell-culture assembly prior to collagen coating; C: Singular channel of
the simulator with cells seeded in the encircled area.

Passage 4 VSMCs cultured in media containing 25 mM D-Glucose were trypsinized (Corning, 25050-CI) and counted using scepter cell-counter (Millipore, PHCC00000) and seeded at a density
of 3.6 x 104 cells/cm 2 or 100,000 cells per well/loading station and allowed to attach and spread
for 36 hours in cell culture media containing 10% FBS, 1% Ab/Am and 25 mM dimethyl sulfoxide
(DMSO). After 36 hours, media was changed to DMEM containing 1% FBS, 1% Ab/m and 1%
Dextran (Sigma, 9004-54-0) to induce quiescence and adjust media viscosity respectively. Briefly,
cells were subjected to media supplemented with 10 ng/mL insulin (Sigma, I0516) during induction
of quiescence and mechanical loading to represent insulin administration whereas for insulin-
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resistance, cells were subjected to media supplemented with 100 nM wortmannin dissolved in
DMSO (Sigma, W1628) during cell-seeding, induction of quiescence and loading (Table 3). DMSO
was added to all treatments since it was required for dissolving wortmannin which was used for
two treatments – wortmannin and insulin-wortmannin. Upon completion for every loading
condition for each respective treatment, cells were rinsed with sterile 1x DPBS for 1-2 minutes and
were subsequently detached using 1mL/well of trypsin-EDTA treatment and assayed using flow
cytometry for cell-cycle and apoptosis analysis or protein extraction or fluorescent imaging for
evaluating cellular hypertrophy.
Table 3: Experimental treatments for aim 1
Treatment

Unloaded (Cells

Cyclic Tensile (CT) (0-

Cyclic Tensile Shear

seeded in 12-well

7 % cyclic strain, 0.5 Hz

(CTS) (0-7 % cyclic

plates)

for 24 hours)

strain, 0.5 Hz for 24 hours
with shear from flow ~ 0.3
dynes.cm-2)

(D)

DMSO Control

Loading
DU: Cells in media

DCT: Cells in media

DCTS: Cells in media

containing 25 mM

containing 25 mM

containing 25 mM DMSO

DMSO during seeding

DMSO during seeding

during seeding (36 hours),

(36 hours), induction of

(36 hours), induction of

induction of quiescence

quiescence (24 hours)

quiescence (24 hours)

(24 hours) and CT-

and unloaded (24

and CT-loading (24

loading w/ low-shear

hours).

hours).

stress (24 hours).
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(DW)
(DI)

DMSO w/ Wortmannin (100 nM)
DMSO + Insulin (10 ng/mL)

DWU: Cells in media

DWCT: Cells in media

DWCTS: Cells in media

containing 25 mM

containing 25 mM

containing 25 mM DMSO

DMSO + 100 nM

DMSO + 100 nM

+ 100 nM Wortmannin

Wortmannin during

Wortmannin during

during seeding (36 hours),

seeding (36 hours),

seeding (36 hours),

induction of quiescence

induction of quiescence

induction of quiescence

(24 hours) and CT-

(24 hours) and

(24 hours) and CT-

loading w/ low-shear

unloaded (24 hours).

loading (24 hours).

stress (24 hours).

DIU: Cells in media

DICT: : Cells in media

DICTS: Cells in media

containing 25 mM

containing 25 mM

containing 25 mM DMSO

DMSO during seeding

DMSO during seeding

during seeding (36 hours),

(36 hours), 25 mM

(36 hours), 25 mM

25 mM DMSO + 10

DMSO + 10 ng/mL

DMSO + 10 ng/mL

ng/mL insulin during

insulin during induction

insulin during induction

induction of quiescence

of quiescence (24

of quiescence (24

(24 hours) and CT-

hours) and unloaded

hours) and CT-loading

loading w/ low-shear

(24 hours).

(24 hours).

stress (24 hours).
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(DWI)

DMSO w/ Wortmannin (100 nM) + Insulin (10 ng/mL)

DWIU: Cells in media

DWICT: Cells in media

DWICTS: Cells in media

containing 25 mM

containing 25 mM

containing 25 mM DMSO

DMSO + 100 nM

DMSO + 100 nM

+ 100 nM Wortmannin

Wortmannin during

Wortmannin during

during seeding (36 hours),

seeding (36 hours), 25

seeding (36 hours), 25

25 mM DMSO + 100 nM

mM DMSO + 100 nM

mM DMSO + 100 nM

Wortmannin + 10 ng/mL

Wortmannin + 10

Wortmannin + 10 ng/mL

insulin during induction of

ng/mL insulin during

insulin during induction

quiescence (24 hours) and

induction of quiescence

of quiescence (24

CT-loading w/ low-shear

(24 hours) and

hours) and CT-loading

stress (24 hours).

unloaded (24 hours).

(24 hours).

3.2c. Mechanical Loading: Cells were subjected to either physiological cyclic strain (0-7%) at 0.5
Hz (CT) or to cyclic tensile strain (0-7% at 0.5 Hz) and low wall shear stress (CTS, ~0.30 dynes.cm2

) from externally supplied flow at 350 mL/min using a peristaltic pump (CTS) for all treatments

(Table 3). Cyclic strain was applied using FlexCell-3000TM system (Flexcell International, NC)
where shear stress was provided by externally supplied flow at 350 mL/min using a peristaltic pump
(Cole-Parmer). Physiologically, VSMCs are subjected to 0-7% cyclic strain in a healthy blood
vessel and typically never experience direct blood flow. Typically, the loading frequency in
previous investigations is 1 Hz but in the current investigation we used 0.5 Hz to represent
physiological profile due to mechanical limits of the design where significant differences were
observed in applied vs theoretical strain (Appendix B). Previous studies have indicated frequency
of mechanical loading to be correlated with altered cell-response however, this effect was only
observed for short-duration of loading with no difference in PI3/AKT or p-ERK 1/2 expression
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levels (194). However, in case of endothelial dysfunction or damage the underlying layer of
VSMCs now experiences shear stress from blood flow directly. After stent implantation, flow
separation zones are created due to stent struts which can result in zones of no-flow or area of flow
separation. The zones typically have very low wall shears-tress. All simulations were performed
at 37 0C in an incubator (Fisher Scientific). Cells were subjected to unloaded/static conditions for
each respective treatment (Control-C, Wortmannin-W, Insulin-I or Insulin + Wortmannin-InsW)
whereby, these samples served as loading controls.

3.2d. Cell cycle analysis: Cell cycle analysis was performed using propidium iodide staining
method using the Guava cell-cycle flow cytometric assay and manufacturer’s protocol (Millipore,
4500-0220)(195,196). Briefly, cells were detached at the end of every simulation using trypsinizedEDTA and were centrifuged at 500x g for 5 minutes. Subsequently, cells were rinsed in 1x DPBS
and re-centrifuged for 5 minutes at 500x g. Cells were redissolved in 200 µL of 1x DPBS and fixed
in ice-cold 70% ethanol with gentle-intermittent shaking and stored at -20 0C for 48 hours at least.
On the day of the assay, cells were removed from ethanol, rinsed in 1x DPBS and resuspended in
200 µL of guava cell-cycle reagent after which they were incubated in dark conditions for 30
minutes at room temperature. Finally, cells were assayed for their distribution within the cell cycle
with Guava HT flow cytometer. For each sample, the threshold cellular count was set to 2000
events.

3.2e. Apoptosis analysis: Apoptotic analysis was performed using the TUNEL assay (Millipore
4500-0121), where cells undergoing apoptosis were incorporated with fluorescently labeled dUTP
and subsequently assay for their intensity using Guava flow cytometer. Cells were detached and
fixed in 70% ethanol similarly to cell-cycle analysis, for measuring apoptotic index for all
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treatments and on the day of the assay, cells were first incubated with a reaction mixture containing
dUTP monomers for 1 hour and subsequently incubated with Anti-BrDU antibody, according to
manufacturer’s protocol (196).

3.2f. Cellular Hypertrophy: Measurement of cellular hypertrophy was performed as described
previously (192). Briefly, cells after each treatment were fixed and permeabilized with 0.2% Triton
X-100 in PBS following which cells were incubated with rhodamine-phalloidin (P1951, Sigma;
1:2000) and DAPI (1:2000) in PBS. Cells were imaged using fluorescent microscope (Digital
inverted microscope, EVOS f1, AMG). For each sample, five to six random field-of-view were
recorded and analyzed per sample, resulting in a total sample size of 180 per experimental group.
Cell area (indicative of cellular hypertrophy) and aspect ratio (major axis length to minor axis
length ratio) were measured using ImageJ software (Open source imaging software from National
Institute of Health). Mean cell area (µm2) & aspect ratio were measured and analyzed for a sample
size of 180 per treatment (192).

3.2g. Protein extraction and Western blotting: Protein quantification was performed using western
blot analysis using a modified version of a previously described protocol (197). Whole cell lysates
were prepared from the cells at the end of each simulation using extraction buffer (20 mM Tris 1%
SDS, 0.5% Triton and 10 µL/mL protease inhibitor cocktail, Sigma P 8340). Total protein
concentration was calculated using BCA-assay kit (Life Technologies, 23225) using BSA know
standards as described by manufacturer. SDS-PAGE was performed using Mini-PROTEAN TGX
10% precast-gels (BioRad 4561034). For each well, 10 µg of total protein was loaded using 5x
loading buffer and electrophoresis was performed at 110 V for 90 minutes. Protein samples were
subsequently transferred to PVDF membranes (BioRad 1620177) at 100V for 75 minutes under
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ice-cold conditions. Blots were blocked with 3% BSA in PBS and were probed with primary
antibodies overnight at 4 0C (SM α-actin ab 119952, 1:500; SM-22α, ab10135 1:1500; α-tubulin,
ab7291 1:1500; p-AKT 4060s Cell signaling technologies 1:1000; p-ERK ½ 4370s Cell signaling
technologies 1:1000). Luminol was used as a chemiluminescence-substrate (Santa Cruz, SC-2048)
reagent prior to blot-imaging. Densitometric analysis was performed using ImageJ software to
quantify the amount of protein expressed. Prior to analysis, all protein bands were normalized with
α-tubulin, which was the loading control.

3.2h. Statistical analysis: Statistical Analysis was performed with One-way ANOVA and Tukey’s
HSD post hoc for all data sets with 0.05 level of significance (α = 0.05). All tests were performed
with JMP 12 pro and plots were created with OriginPro 2017. “*” represents statistical significance
when compared to control treatment within each respective loading. “#” represents statistical
significance between treatments during CT and CTS loading.
3.3: Results
3.3a. Cell-cycle distribution: Cell cycle distribution was analyzed using the propidium-iodide
staining method with Guava cell-cycle kit (n=6 for each treatment within every loading) which
provides cellular-distribution within the cell-cycle depending upon fluorescent-intensity (198).
Effect of treatment and loading was evaluated across the cell cycle and distributions within each
phase – G1/G0, S and G2/M phase were compared. A higher cell-percentage in G2/M or S-phase
represented a more proliferative response since all the cells were passage-matched and conditioned
to quiescence state, prior to any simulation. All cells in the G1/G0 phase are represented with the
first peak of histograms whereas cells in the G2/M phase were gated for double the intensity of
G1/G0 phase. Cells between these two peaks were recorded as cells in the stationary phase or Sphase (Figure 7) and cell-cycle results are summarized in table 4.
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Figure 7: Treatment
and
loading-wise
cell-cycle
distribution of cells.
Each sample was
assayed for 2000
cells. First peak
represents % cells in
the G1/G0 phase
whereas second peak
represents % cells in
G2/M phase. All cells
in between these two
distinct peaks were
categorized in the sphase.

Table 4: Cell-cycle results

Loading

Unloaded

CT

CTS

% Cells in

% Cells in S-

% Cells in

Sample

G1/G0 phase

phase

G2/M phase

Name

(Mean±SD)

(Mean±SD)

(Mean±SD)

Control

77.05±3.56

5.35±1.05

15.15±1.63

DU

Wortmannin

78.68±3.32

6.08±0.75

12.05±1.77

DWU

Insulin

53.15±3.88

9.93±1.52

27.77±3.64

DIU

InsW

64.73±6.63

8.58±0.95

26.47±1.93

DWIU

Control

85.8±3.39

3.56±1.47

9.27±1.54

DCT

Wortmannin

84.83±2.76

5.28±0.92

9.55±1.84

DWCT

Insulin

67.55±5.94

9.97±1.64

25.75±2.06

DICT

InsW

66.85±2.26

8.51±1.29

22.21±2.72

DWICT

Control

78.42±2.06

6.63±1.07

11.95±1.64

DCTS

Wortmannin

75.05±6.81

7.81±1.77

14.62±2.35

DWCTS

Insulin

53.1±3.56

9.43±1.76

37.47±2.25

DICTS

InsW

56.01±4.92

7.49±1.00

26.70±3.01

DWICTS

Treatment
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Comparison of all treatments with DMSO control for each loading revealed that insulin treatment
led to significantly lower % cells in the G1/G0-phase for all mechanical loading (p-value < 0.0001
for DIU vs DU; DICT vs DCT; DICTS vs DCTS, Figure 8) and a corresponding increase in %cells in the S phase (p-value < 0.0001 for DIU vs DU; DICT vs DCT; DICTS vs DCTS, Figure 9)
and G2/M phase (p-value < 0.0001 for DIU vs DU; DICT vs DCT; DICTS vs DCTS, Figure 10).
Cellular-treatment with 100 nM wortmannin did not result in significantly different % cells in
G1/G0 or S or G2/M phase, in comparison to DMSO control across all loadings. Similar to insulin
treatment, InsW treatment also demonstrated significantly reduced % cells in the G1/G0-phase for
mechanical loading (p-value < 0.0001 for DWIU vs DU; DWICT vs DCT; DWICTS vs DCTS)
and a corresponding increase in %-cells in the S phase (p-value < 0.0001 for DIU vs DU; DICT vs
DCT; DICTS vs DCTS) and G2/M phase (p-value < 0.0001 for DIU vs DU; DICT vs DCT; DICTS
vs DCTS) however, the results were not significantly different from insulin-only treatment.

Figure 8: Treatment-wise percentage of cells in the G1/G0 phase within each mechanical
loading; Values represented as Mean ± SD for every treatment (n=6 for each). ‘*’ represents
statistical significance (p-value < 0.05) in comparison to ‘control or DMSO’ for every loading;
‘#’ represents statistical significance (p-value < 0.05) in comparison to cyclic-tensile (CT). All
comparisons performed with one-way ANOVA and Tukey’s HSD.
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Figure 9: Treatmentwise percentage of
cells in the S- phase
within each
mechanical loading;
Values represented as
Mean ± SD for every
treatment (n=6 for
each). ‘*’ represents
statistical significance
(p-value < 0.05) in
comparison to
‘control or DMSO’
for every loading with
one-way ANOVA and
Tukey’s HSD post-hoc
comparison.

Figure 10: Treatment-wise percentage of cells in the G2/M- phase within each mechanical
loading; Values represented as Mean ± SD for every treatment (n=6 for each). ‘*’ represents
statistical significance (p-value < 0.05) in comparison to ‘control or DMSO’ for every loading;
‘#’ represents statistical significance (p-value < 0.05) in comparison to cyclic-tensile (CT). All
comparisons performed with one-way ANOVA and Tukey’s HSD.
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Corroborating with the effects of insulin, concomitant application of low-shear stress and cyclicstrain further led to lower % of cells in the G1/G0-phase in comparison to CT only (p-value <
0.0001 for DICT vs DICTS and DWICT vs DWICTS) and a corresponding increase in % of cells
in the S phase (p-value < 0.0001 for DICT vs DICTS and DWICT vs DWICTS) and G2/M phase
(p-value < 0.0001 for DICT vs DICTS and DWICT vs DWICTS). In addition, insulin
administration resulted in significantly greater % of cells during CTS loading in comparison to CT
(p-value < 0.0001 for DICTS vs DICT) and in comparison to InsW treatment (p-value < 0.0001 for
DICTS vs DWICTS). These observations indicate that under clinically relevant cyclic-strain and
low-shear application, insulin exerts a pro-proliferative effect on RASMCs while selective-insulin
resistance through wortmannin treatment did not influence cell-cycle progression.
3.3b. Apoptotic Index: For evaluating the total percentage of cells undergoing apoptosis samples
were quantified by the TUNEL assay, using Guava flow cytometer (n=6 for each treatment per
loading). Cell-distribution for each treatment within every loading is depicted in figure 11 where
the first peak represents cells that are TUNEL-negative and the second peak for TUNEL-positive
cells. Results are summarized in table 5 and plotted as percent apoptosis – defined as ratio of percent
apoptotic cells to percent total cells (sum of apoptotic and non-apoptotic cells) (Figure 12).
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Figure 11:
Treatment and
loading-wise
TUNEL positive
cell-distribution.
Each sample was
assayed for 2000
cells. First peak
represents % cells
in the negative for
TUNEL statin
whereas second
peak represents %
cells positive for
TUNEL stain.

Table 5: Guava TUNEL results
Loading

Unloaded

CT

CTS

Treatment

% Apoptotic cells

Sample Name

Mean ± SD

Control

10.97 ± 1.12

DU

Wortmannin

15.97 ± 0.94

DWU

Insulin

6.14 ±1.29

DIU

InsW

16.26 ± 1.77

DWIU

Control

19.29 ± 0.88

DCT

Wortmannin

24.12 ± 1.35

DWCT

Insulin

18.76 ± 1.03

DICT

InsW

24.92 ± 1.58

DWICT

Control

29.12 ± 0.83

DCTS

Wortmannin

36.01 ± 1.14

DWCTS

Insulin

29.19 ± 2.49

DICTS

InsW

39.47 ± 0.95

DWICTS
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For unloaded samples, insulin treatment significantly reduced overall apoptosis however, this effect
was not extended to CT or CTS loadings where the results were not significantly different from the
DMSO control thus, demonstrating the contribution of mechanical loading in inducing cellular
apoptosis. Wortmannin appeared to induce apoptosis since InsW treatment resulted in similar
measurements as for wortmannin treatment, where InsW treatment led to significantly greater
number of cells undergoing apoptosis as compared to DMSO control for all loadings (p-value <
0.0001 for DWIU vs DU; DWICT vs DCT; DWICTS vs DCTS) (figure 12). In addition, InsW
treated cells did not exhibit significantly greater number of cells undergoing apoptosis in
comparison to wortmannin treated cells thus, indicating wortmannin primarily resulted in greater
apoptosis.

Figure 12: Treatment-wise percent apoptosis within each mechanical loading; Values
represented as Mean ± SD for every treatment (n=6 for each). ‘*’ represents statistical
significance (p-value < 0.05) in comparison to ‘control or DMSO’ for every loading; ‘#’
represents statistical significance (p-value < 0.05) in comparison to cyclic-tensile (CT). All
comparisons performed with one-way ANOVA and Tukey’s HSD.
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Application of CT led to significantly greater number of cells undergoing apoptosis as compared
to unloaded samples for all treatments (p-value < 0.0001 for CT vs U within each treatment)
whereas application of low-shear stress further contributed to induction of apoptosis (p-value <
0.0001 for CTS vs CT within each treatment).
3.3c. Cellular hypertrophy: Cellular hypertrophy was evaluated by measuring the cell-area and
aspect ratio (Ratio of major-axis length to minor-axis length) using image analysis with ImageJ
software. Hypertrophic cells exhibit greater cell area either due to increased protein secretion or
relatively loose F-actin fibers while rhomboid-shaped cells will have lower aspect ratio as
compared to spindle-shaped cells thus indicative of synthetic phenotype (192). Results for cell-area
and aspect ratio are summarized in table 6 and rhodamine-phalloidin stained images for all
treatments within each loading is compiled in Figure 13.

Table 6: Cell-area and aspect ratio results
Loading

Unloaded

CT

CTS

Cell area (sq.

Aspect Ratio

µm) Mean± SD

Mean± SD

Control

5125.24 ± 94.05

1.67 ± 0.02

DU

Wortmannin

5172.09 ± 107.11

1.75 ± 0.05

DWU

Insulin

5372.98 ± 95.32

1.68 ± 0.03

DIU

InsW

5512.38 ± 84.23

1.80 ± 0.04

DWIU

Control

2460.64 ± 54.36

2.76 ± 0.08

DCT

Wortmannin

2686.14 ± 99.03

2.46 ± 0.05

DWCT

Insulin

3620.26 ± 80.31

2.05 ± 0.06

DICT

InsW

3636.81 ± 79.97

2.09 ± 0.04

DWICT

Control

2994.73 ± 65.75

2.31 ± 0.05

DCTS

Wortmannin

3097.84 ± 84.39

2.22 ± 0.06

DWCTS

Insulin

4362.94 ± 88.67

1.84 ± 0.23

DICTS

InsW

4464.68 ± 83.73

1.92 ± 0.03

DWICTS

Treatment
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Sample Name

Figure 13: Rhodamine-phalloidin stained images with treatments as rows and mechanical
loadings as columns; Scale-bar 400 µm
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As demonstrated in figure 14, insulin treatment led to significantly greater cell-area for
mechanically loaded samples in comparison to DMSO controls (p-value < 0.0001 for DICT vs
DCT; DICTS vs. DCTS) thus, demonstrating a combined effect of insulin treatment and
physiologically relevant mechanical loading where cells exhibit greater cell-area under loaded
conditions. Further, wortmannin treatment did not result in significant change in cell-area
independent of loading. Similar to the results from insulin during mechanical loading, InsW
treatment resulted in significantly greater cell area, in comparison to controls (p-value < 0.001
DWICT vs DCT; DWICTS vs. DCTS) albeit, no significant differences between InsW and insulin
treatment within each respective loading. These results indicate a relatively greater hypertrophic
response in RASMCs due to insulin treatment under CT and CTS loading with no significant effect
to due to selective insulin resistance.

Figure 14: Treatmentwise Cell area (sq. µm)
within each mechanical
loading; Values
represented as Mean ±
SD for every treatment
(n=6 for each with 180
cells per sample). ‘*’
represents statistical
significance (p-value <
0.05) in comparison to
‘control or DMSO’ for
every loading with oneway ANOVA and
Tukey’s HSD post-hoc
comparison.

In accordance with cell-area results, aspect ratio measurements (figure 15) demonstrated that
insulin treatment led to a significantly lower aspect ratio for CT and CTS loading (p-value < 0.0001
for DICT vs DCT; DICTS vs DCTS) whereas wortmannin treatment did not induce significant
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changes in aspect ratio across all loadings thus, supporting cell-area measurements. As with insulin,
InsW treatment also demonstrated significantly lower aspect ratio for CT and CTS loading in
comparison to control (p-value < 0.0001 DWICT vs DCT; DWICTS vs. DCTS). With no
significant differences between insulin and InsW treatment across all loadings, selective insulinresistance did not influence cellular hypertrophy whereas insulin treatment promoted cellular
hypertrophy as estimated by significantly greater cell-area and correspondingly lower aspect ratio
measurements.

Figure 15: Treatmentwise Aspect-ratio
within each mechanical
loading; Values
represented as Mean ±
SD for every treatment
(n=6 for each with 180
cells per sample). ‘*’
represents statistical
significance (p-value <
0.05) in comparison to
‘control or DMSO’ for
every loading with oneway ANOVA and
Tukey’s HSD post-hoc
comparison.
3.3d. Protein Expression: Protein expression was measured with western blotting and results were
normalized to α-Tubulin (50 kDa), which served as the loading control. Smooth muscle cellcontractile state was evaluated by comparing the expression of contractile-state associated markers
–α-SM actin and SM22 α with reduced expression decreases as cells switch to
proliferative/synthetic phenotype. Further, to evaluate if wortmannin treatment was effective in
inducing selective insulin-resistance, expression of phosphorylated-AKT (p-AKT) was evaluated
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for all treatments whereas phosphorylated-ERK ½ (p-ERK ½) expression was evaluated to verify
the potential molecular track through which the cellular response acts.
As shown in figure 16, insulin administration led to significantly lower expression of α-SM actin
for unloaded, CT and CTS loading conditions in comparison to control (p-value < 0.0001 for DIU
vs DU; DICT vs DCT; DICTS vs DCTS) thus, indicating a shift towards greater synthetic-state.
Similar results with InsW treatment were observed where significantly lower α-SM actin
expression was observed in comparison to DMSO controls across all loadings (p-value < 0.0001
DWIU vs DU; DWICT vs. DCT; DWICTS vs DCTS) further confirming insulin’s effect in
inducing a synthetic-state response.

Figure 16: Treatment-wise α-SM actin expression normalized to α-Tubulin expression within
each mechanical loading; Values represented as Mean ± SD for every treatment (n=6 for
each). ‘*’ represents statistical significance (p-value < 0.05) in comparison to ‘control or
DMSO’ for every loading with one-way ANOVA and Tukey’s HSD post-hoc comparison.
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Wortmannin treatment led to greater expression of α-SM actin for unloaded (p-value < 0.0001 for
DWU vs DU) and CTS loading (p-value < 0.0001 for DWCTS vs DCTS) thus, indicating a procontractile state shift of RASMCs under these conditions. With InsW treatment, results were
observed to be very similar to insulin treatment where significantly lower expression of α-SM actin
was observed across all loadings (p-value < 0.0001 for DWIU vs DU; DWICT vs DCT; DWICTS
vs DCTS). However non-significant differences between insulin and InsW treatment indicate the
involvement of insulin under these conditions whereby insulin promotes dedifferentiation of
RASMCs overall.
Similarly, SM22 α expression results (Figure 17) indicate that insulin treatment led to significantly
lower expression of SM22 α for unloaded (p-value < 0.0001 for DIU vs DU), CT (p-value < 0.0001
for DICT vs DCT) and CTS loading (p-value < 0.0001 for DICTS vs DCTS). In combination with
the actin-expression results, these results indicate that insulin administration leads greater
dedifferentiation of RASMCs since both the contractile-state associated markers have significantly
lower expression. Wortmannin treatment did not result in significant changes in the expression of
SM22 α across all loadings. In addition, InsW treatment led to significantly lower expression of
SM22 α for unloaded (p-value < 0.0001 for DWIU vs DU), CT (p-value < 0.0001 for DWICT vs
DCT) and CTS (p-value < 0.0001 for DWICTS vs DCTS) with no significant difference between
InsW and insulin treatment. These results confirm that insulin treatment leads to greater phenotypic
modulation of RASMCs towards the synthetic state and thus, demonstrates lack of influence of
selective insulin-resistance in mediating a phenotypic change in RASMCs. Different mechanical
loadings did not impact contractile-state markers for each respective treatment however, insulin
administration led to lower α-SM actin and SM22 α expression with the application of shear when
compared respective cyclic-tensile treatments (p-value < 0.0001 for DICT vs DICTS).
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Figure 17: Treatment-wise SM22α expression normalized to α-Tubulin expression within each
mechanical loading; Values represented as Mean ± SD for every treatment (n=6 for each). ‘*’
represents statistical significance (p-value < 0.05) in comparison to ‘control or DMSO’ for
every loading with one-way ANOVA and Tukey’s HSD post-hoc comparison.

In order to confirm the efficacy of wortmannin in inducing selective insulin resistance through
inhibiting phosphorylation of AKT, expression levels of p-AKT were compared for all treatments
within each loading. As shown in figure 18, wortmannin treatment did in fact suppressed expression
of p-AKT across all loadings with significantly lower for unloaded (p-value < 0.0001 for DWU vs
DU), CT (p-value < 0.0001 for DWCT vs DCT) and CTS (p-value < 0.0001 for DWCTS vs DCTS).
In addition, significantly reduced expression of p-AKT was also observed for InsW treatment for
unloaded (p-value < 0.0001 for DWIU vs DU), CT (p-value < 0.0001 for DWICT vs DCT) and
CTS (p-value < 0.0001 for DWICTS vs DCTS). These results indicate that 100 nM wortmannin
treatment did reduce expression of p-AKT significantly across all loadings.
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Figure 18: Treatment-wise p-AKT expression normalized to α-Tubulin expression within each
mechanical loading; Values represented as Mean ± SD for every treatment (n=6 for each). ‘*’
represents statistical significance (p-value < 0.05) in comparison to ‘control or DMSO’ for
every loading with one-way ANOVA and Tukey’s HSD post-hoc comparison.

Expression of p-ERK ½ were compared as a direct marker of cellular proliferation (Figure 19).
ERK-1/2 phosphorylation is known to occur during cell cycle progression and cellular proliferation
both of which are indirect indicators of phenotypic modulation. From figure 19, it can be observed
that the insulin treatment led to a greater expression of phosphorylated p-ERK ½ for unloaded (pvalue < 0.0001 for DIU vs DU), CT (p-value < 0.0001 for DICT vs DCT) and CTS (p-value <
0.0001 for DICTS vs DCTS). Similar results were observed for InsW treatment where significantly
greater expression of p-ERK ½ was observed for unloaded (p-value < 0.0001 for DWIU vs DU),
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CT (p-value < 0.0001 for DWICT vs DCT) and CTS (p-value < 0.0001 for DWCTS vs DCTS).
With wortmannin treatment, expression of p-ERK ½ was not significantly different, independent
of mechanical loading. This effect is further confirmed when comparing InsW and insulin treatment
under CTS loading where insulin treatment led to significantly greater expression of p-ERK ½ in
comparison to InsW treatment (p-value < 0.0001 for DICTS vs DWICTS).

Figure 19: Treatment-wise p-ERK 1/2 expression normalized to α-Tubulin expression within
each mechanical loading; Values represented as Mean ± SD for every treatment (n=6 for each).
‘*’ represents statistical significance (p-value < 0.05) in comparison to ‘control or DMSO’ for
every loading with one-way ANOVA and Tukey’s HSD post-hoc comparison.

Overall results from this investigation are summarized in table 7 and demonstrate that inducing
selective-insulin-resistance did not alter the phenotypic state of RASMCs significantly whereas
insulin administration resulted in greater phenotypic modulation of RASMCs and much greater for
insulin administration under clinically relevant mechanical loading conditions of cyclic strain and
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low wall-shear stress as evidenced from greater number of cells in G2/M and S-phase of the cell
cycle, greater apoptosis, reduced expression of contractile-state associated markers and greater
expression of phosphorylated ERK-1/2. Combination of wortmannin with insulin administration
did not result in significant changes in comparison to insulin groups. Thus, these results indicate a
pro-proliferative/greater phenotypic modulation in RASMCs under clinically relevant mechanical
loading when supplemented with insulin, while selective insulin-resistance did not influence
proliferation or phenotypic modulation of RASMCs under these conditions.

*
DMSO +
Insulin
(10 ng/mL)

DMSO +
Wortmannin
(100 nM) +
Insulin (10
ng/mL)

*

*

*

*

*

*

*

*

*

*

*

*

*

*

Group

*

p-AKT

*

p-ERK
1/2

*

SM22α

Actin

*

DMSO +
Wortmannin
(100 nM)

Aspect
Ratio

Area

TUNEL

Treatment

Cell
Cycle

Table 7: Summary of all treatment and loading-wise comparison where each respective row
represents a group (‘Group’ column) within treatments. Results represented were compared to
the treatment-control (DMSO) for its respective mechanical loading (Unloaded or CT or CTS).

*

DWU

*

DWCT

*

DWCTS

*

*

*

DIU

*

*

*

DICT

*

*

*

*

DICTS

*

*

*

*
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*

DWIU

*

*

*

DWICT

*

*

*

DWICTS

3.4: Discussion
Clinical investigations have consistently demonstrated insulin administration a risk factor for
developing in-stent restenosis (ISR) following angioplasty (199) for bare metal stents (91) and first
(200) and second-generation drug eluting stents (102,106). Although the exact mechanisms
resulting in greater neointimal hyperplasia in diabetic patients remains unclear, diabetes itself
represents the most significant predictor of developing ISR owing to multiple co-existing
complications such as hyperglycemia, insulin resistance, insulin administration, elevated
triglyceride levels, hypertension, each resulting in significantly greater proliferation of vascular
smooth muscle cells (201).
Previously we have demonstrated that chronic high glucose resulted in greater proliferation and
phenotypic modulation of RASMCs under dynamic loading as compared to low glucose controls
(192). Clinically, diabetic patients are afflicted with insulin resistance and may require insulin
administration (202).

In the current study, we investigated if clinically relevant insulin

administration (10 ng/mL) and selective partial insulin resistance (wortmannin 100 nM) influenced
dedifferentiation and phenotypic modulation of RASMCs under dynamic loading. We
hypothesized that insulin administration will promote proliferation and dedifferentiation of
chronic-high glucose acclimated RASMC and this effect will be magnified in case of induced
insulin-resistance. In order to ensure that cellular passaging did not interfere with dedifferentiation
of cells, we strictly employed passage 4 RASMCs for all the experiments in the study. Effects of
combined mechanical loading with cyclic strain and low wall-shear stress under insulin
administration and selective insulin-resistance have not been explored by others to our knowledge.
This study was aimed at capturing cellular response for diabetes-specific conditions more
accurately than conventional static/unloaded conditions using clinically relevant mechanical forces.
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The process of cellular proliferation is governed by the progression of the cell and its components
through the process of cell-cycle whereby, cells under non-proliferative or quiescent-state remain
in the G1/G0 phase and do not pass this checkpoint. However, under the influence of proliferative
triggers, cascade of molecules are activated, consequently moving to subsequent phases of S and
then G2/M (203). Cell-cycle analysis using flow-cytometry revealed that the administration of
insulin to chronic high-glucose acclimated cells resulted in a significantly lower percentage of cells
in the G1/G0 phase (p-value < 0.0001 for DMSO control vs insulin across all loadings and
concurrently greater percentage of cells in the S-phase (p-value < 0.0001 for DMSO control vs
insulin across all loading) and the G2/M-phase (p-value < 0.0001 for DMSO control vs insulin
across all loading) indicative of a proliferative response independent of mechanical loading.
However, insulin administration associated low shear-stress and physiologically relevant
circumferential strain observed locally after stent implantation resulted in significantly greater %
cells in the G2/M-phase in comparison to cyclic-tensile loading. This observation is indicative of
the significance of low shear-stress on cellular-response (p-value < 0.0001 for DICTS vs DICT).
The current results support previously published work by others where insulin has been
demonstrated to exert pro-proliferative effects on VSMCs (141,188,204) with greater neointimal
hyperplasia (15,32) with clinical evidence (70,107). Induction of selective insulin-resistance by
incubating cells with 100 nM wortmannin did not significantly alter %cells in the G1/G0,S or G2/M
phase for all loadings indicating that further exploration of pathways is required before AKT
phosphorylation can be leveraged to mimic insulin-resistance at the cellular level in RASMCs while
subjected to clinically relevant circumferential strain and low wall-shear stress. In fact, in this study,
inhibiting AKT phosphorylation with wortmannin did not influence cell-cycle progression of
chronic high glucose acclimated RASMCs. These observations are further supported by non-
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significant difference in cell-cycle progression due to InsW treatment in comparison to insulin
treatment.
In order to evaluate the impact of treatments on induction of apoptosis, cells were analyzed for
TUNEL expression using flow-cytometric assay. Application of mechanical forces has been
previously reported to induces apoptosis in RASMCs (205). Our results are consistent with these
observations where circumferential strain led to a significantly greater % TUNEL-positive cells in
addition to higher % TUNEL-positive cells for concomitant strain and low shear stress. insulin
administration led to lower apoptosis in comparison to DMSO controls under mechanical loading
thus indicating pro-survival effect of insulin on RASMCs. Previous animal studies and in vitro
investigations have demonstrated a pro-survival effect of insulin where insulin treatment led to a
significant reduction in cells undergoing apoptosis (206). In the current investigation as well,
insulin administration resulted in reduced apoptosis during unloaded conditions however this effect
was not extended to CT or CTS loading hence underscoring the importance of mechanical loading.
In contrast, wortmannin treatment resulted in significantly greater % TUNEL-positive cells for
unloaded, CT and CTS thus, indicating pro-apoptotic effect of inhibiting AKT-phosphorylation.
These results have been confirmed in previous investigation where wortmannin treatment was
observed to promote apoptosis in VSMCs in vitro (206) and due to similar mechanical loading
(192). Further, similar results were observed for InsW treatment where significantly greater %
TUNEL-positive cells were observed across all loadings, in comparison to DMSO controls.
However, these results were not significantly different than wortmannin treatment demonstrating
lower efficacy of insulin in control apoptosis during partially insulin resistant state.
Cell-area and aspect ratio (major axis length to minor axis length) are indirect indicators of cellular
hypertrophy where a hypertrophic response is estimated by greater cellular area and
correspondingly lowered aspect ratio. Within the phenotypic continuum, VSMCs exhibit different
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morphologies depending upon their differentiated state with contractile-state is associated with
longer and narrower cells resulting in lower cell area and higher aspect ratio and synthetic-state is
associated with greater cell area and lower aspect ratio (207). In the current investigation, insulin
administration resulted in significantly greater cell-area and correspondingly lower aspect ratio for
chronic high glucose acclimated cells subjected to physiological strain and low shear stress in
comparison to DMSO controls (p-value < 0.0001 for DICTS vs DCTS). Using other indicators,
previous investigations with insulin administration have demonstrated insulin to induce cardiac
hypertrophy in animal models (208) and in vitro investigations with VSMCs (209). In addition,
previous studies have also demonstrated a reduced hypertrophic response to physiologically
relevant strain and application of low shear stress to these conditions resulted in greater hypertrophy
(192,210). These results are in agreement with the current observation and provided investigational
validation to our results. Wortmannin treatment did not significantly alter cell area or aspect ratio
in the absence of insulin across all loading conditions and these results are consistent with
previously reported results. Further non-significant differences between InsW and insulin treatment
indicate that inhibiting phosphorylation of AKT may not influence cell area or aspect ratio.
Expression of contractile-state associated protein markers are a direct estimate of VSMC
differentiation of the phenotypic continuum. In the current study, we investigated the expression of
αSM actin and SM22α which are predominantly observed in the contractile phenotype of RASMCs
and with dedifferentiation to a synthetic state, their expression is reduced. Administration of insulin
resulted in a significantly reduced expression of αSM actin for unloaded (p-value < 0.0001 for DIU
vs DU), CT (p-value < 0.0001 for DICT vs DCT) and CTS loading (p-value < 0.0001 for DICTS
vs DCTS) in comparison to DMSO controls thus indicating greater phenotypic dedifferentiation of
RASMCs due to insulin administration. Wortmannin treatment on the contrary resulted in greater
significantly greater expression of αSM actin in comparison to DMSO controls for unloaded (p-
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value < 0.0001 for DWU vs DU) and CTS loading (p-value < 0.0001 for DWCTS vs DCTS)
indicative of relatively greater contractile-phenotype under these conditions. In addition, InsW
treatment resulted in significantly reduced expression of actin in comparison to wortmannin
treatment but were not significantly different than insulin treatment across all loadings. In
agreement with αSM-Actin results, SM22α expression results also indicate a pro synthetic-state
effect of insulin administration while a protective effect of wortmannin treatment with nonsignificant differences between InsW and insulin treatment. These results demonstrate insulin to
be primarily responsible in inducing a synthetic state phenotype in chronic high glucose acclimated
RASMCs independent of wortmannin treatment. Physiologically relevant circumferential strain has
been reported to promote a contractile phenotype with greater expression of actin (183) whereas
application of low shear stress in addition to physiological strain reduced the expression of
contractile-state associate markers (210). Our results agree with previous cellular studies where a
similar response of mechanical loading on actin expression has been reported. Cells isolated from
neointimal lesions of diabetic animals requiring insulin administration and human arterial cells
from diabetic patients have been reported to exhibit reduced expression of contractile state
associated markers (176,211,212). In the current investigation, selectively inhibiting expression of
p-AKT to induce experimental insulin resistance did not result in a significant difference in actin
expression. This necessitates further investigation in deciphering the role of AKT inhibition in
regulating contractile-state markers in smooth muscle cells.
Expression levels of p-AKT were evaluated to confirm if wortmannin treatment resulted in partial
inhibition of AKT-phosphorylation. Wortmannin (100 nM) has been reported to irreversibly inhibit
over 95% phosphorylation of AKT with small incubation times and was primarily the reason of
selection (212). Treatment of chronic high glucose acclimated RASMCs with 100 nM of
wortmannin significantly reduced the expression of p-AKT across all loadings with or without
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insulin administration, in the current investigation. Although the wortmannin did not completely
inhibit p-AKT expression, marked reduction in the expression levels were acceptable for the current
exploratory model since they were significantly lower than the control treatment (p < 0.0001 for
control vs wortmannin across all loadings).
VSMCs have been previously demonstrated to result in greater phosphorylation of ERK ½ proteins
when undergoing cellular proliferation (212). Thus, in addition to cell-cycle progression, greater
expression of these markers indicates a proliferative cellular-response. In the current investigation,
insulin administration resulted in greater expression of p-ERK ½ markers for unloaded, CT and
CTS loadings in comparison to DMSO controls. Wortmannin treatment however did not alter pERK ½ expression significantly under any loading in comparison to controls. Similar to insulin
treatment, InsW treatment also resulted in significantly greater expression of p-ERK ½ across all
loading conditions. Previously, in vitro studies have demonstrated that VSMCs undergoing
proliferation exhibit greater phosphorylation of ERK ½ (212) and our results are in agreement with
these observations further indicating that insulin exerts a pro-proliferative response on chronic high
glucose acclimated RASMCs.
The currently proposed model successfully captures cellular-response under clinically relevant
mechanical loading (0-7%) and implant associated low wall-shear stress (~ 0.3 dynes.cm-2) in
combination with diabetes-specific complications of chronic high-glucose acclimation (25 mM)
and insulin administration (10 ng/mL). Physiologically, cells VSMCs area subjected to
circumferential strain owing to pulsatile nature of blood-flow and also experience direct flow shear
stress due to barotrauma from PCI, which results in endothelial damages and exposes the
underlying smooth muscle cells to flow. Cellular-response under these conditions captures the
clinically relevant-VSMC response more accurately than conventional static/unloaded conditions
for diabetic patients implanted with arterial stents and requiring insulin administration. With the

83

proposed model, we have successfully shown that insulin administration has pro-proliferative effect
on VSMCs and results in greater phenotypic modulation of chronic high glucose acclimated
RASMCs under dynamic loading conditions.

3.5: Conclusion
Our experimental approach successfully integrates mechanical forces observed in a stented blood
vessel with diabetic patient-related conditions such as chronic high glucose with insulin
administration in vitro. Cellular-response under these conditions has not been performed previously
despite clinical relevancy and demonstrates the need to model cellular behavior under diseaseassociated conditions to further improve prognosis of percutaneous interventional approaches.
Chronic high-glucose acclimated passage 4 RASMCs were subjected to dynamic mechanical
loading comprising of cyclic-tensile strain and low wall-shear stress under diabetes associated
insulin administration and selective insulin resistance. Results underscore the relevance of
subjecting mechanosensitive cells to dynamic loading and the current investigation successfully
combines physiological circumferential strain with implant associated low wall-shear stress under
patient-specific metabolic complications. The exploratory approach of incorporating selective
insulin resistance with wortmannin did not alter smooth muscle cell-phenotype thus, necessitating
further investigation into the potential role of AKT pathway. It was successfully demonstrated that
insulin exerts a pro-proliferative dedifferentiation of RASMCs to a relatively greater syntheticstate, as evidenced by reduced expression of contractile-state associated protein markers (αSM
actin and SM22α) and conformity of current results with previous studies and clinical evidence of
exaggerated restenosis in insulin requiring patients validate our diabetic model. Greater phenotypic
modulation of VSMCs under these patient-specific conditions could serve as targets for
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optimization of clinical treatment for diabetic patients. Future investigations should focus on
exploring the exact mechanisms involved in mediating greater phenotypic modulation of VSMCs
under these conditions. In addition, other patient-specific risk factors or complications can be
combined on this platform to further understand cellular-response under complex clinical
conditions. VSMCs acclimated to chronic high glucose (25 mM D-Glucose for 4-5 weeks) and
subjected 0-7% cyclic strain with low wall-shear stress (~0.3 dynes cm-2) under physiologically
relevant insulin administration (10 ng/mL) demonstrated a more accurate and representative
response as compared to conventional static cultures.
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Chapter 4: “Development and characterization of hypertensive-diabetic cellular response
evaluation model for restenosis”
Purpose: Current study explores the influence of hypertension-associated elevated mechanical
loading combined with stent-associated low wall-shear stress on phenotypic modulation of
RASMCs under diabetes specific chronic high-glucose and insulin administration to propose an in
vitro diabetic-hypertensive cell-response model. As an application, efficacy of sirolimus in
controlling dedifferentiation of RASMCs under hypertensive loading and insulin treatment was
evaluated.
Methods: Passage 4 RASMCs cultured in high-glucose medium were subjected to physiological
cyclic-tensile with low shear stress (NTS) and hypertensive-tensile with low shear stress (HTS) to
evaluate the influence of elevated mechanical strain on vascular smooth muscle cell-phenotype.
Cells were evaluated for their distribution within the cell-cycle, percentage of cells undergoing
apoptosis, estimation of cellular hypertrophy by comparing cell-area and aspect ratio, comparison
of protein expression – αSM actin and SM22α (contractile-state markers); p-ERK ½ (proliferation
marker); Hsp47 (collagen marker). All measurements were compared using one-way ANOVA with
Tukey’s HSD as a post-hoc test.
Results: Subjecting cells to hypertension-associated elevated mechanical strain with low shear
(HTS) resulted in significantly greater % cells in the G2/M (p < 0.0001) and S-phase (p < 0.0001)
of the cell-cycle indicating a pro-proliferative effect in comparison to normotensive controls (NTS)
for all treatments. This effect was augmented with insulin administration as demonstrated by
significantly greater % cells in the G2/M phase for insulin (p < 0.0001 for HITS vs HTS). In
addition, subjecting cells to elevated mechanical strain resulted in significantly greater induction
of apoptosis for all treatments (p < 0.0001 for HTS vs NTS; HITS vs NITS) while insulin
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administration did not influence apoptosis. Hypertensive loading also resulted in greater
dedifferentiation of cells as indicated by significantly reduced expression of contractile-state
associated proteins – αSM-actin and SM22α (p < 0.0001 for HTS vs NTS; HITS vs NITS) with
lesser expression with insulin (p < 0.0001 for HITS vs NITS). Greater proliferation was further
confirmed by significantly higher expression of p-ERK ½ in response to elevated mechanical
loading (p < 0.0001 for HTS vs NTS; HITS vs NITS) which was significantly augmented by insulin
administration (p < 0.0001 for HITS vs HTS). Treatment of cells under diseased associated
conditions with 10 ng/mL sirolimus demonstrated a significantly regulated cellular-response
however, insulin administration still demonstrated greater pro-proliferative response in conjunction
with relatively greater phenotypic modulation in comparison to controls.
Conclusion:
In the current investigation, we successfully combined two clinically relevant patient-specific risk
factors to subject chronic high-glucose acclimated rat aortic smooth muscle cells to complicationsassociated with diabetes and hypertension under altered hemodynamics associated with stentimplantation. This in vitro diabetic-hypertensive cellular-response evaluation concept model can
be used in future, to investigate the efficacy of novel drugs and identification of novel therapeutic
targets aimed at reducing in-stent restenosis in diabetic-hypertensive patients, prior to pre-clinical
evaluation.
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4.1: Introduction:
Clinically, hypertension is a known patient-specific risk associated with poorer prognosis of
percutaneous coronary intervention (PCI) with studies indicating hypertension to be significantly
associated with restenosis (156). In addition, higher rates of myocardial infarction have been
reported in patients afflicted with diabetes and hypertension ultimately suggesting poorer prognosis
of percutaneous coronary intervention (PCI) in these patients (213). A direct outcome of
hypertension is elevated cyclic mechanical strain with almost two-fold increase (15-30%) in
circumferential strain on the arterial wall (214,215).
Elevated mechanical strain has been shown to promote synthetic-phenotype in vascular smooth
muscle cells (216–218) and have been previously documented to exhibit reduced expression of
contractile-state markers alongside elevated cell-proliferation (219–221) and apoptosis (222–225).
Animal models of hypertension have been reported to exhibit greater neointimal hyperplasia in
response to PCI and hypertension is a clinical predictor of target vessel revascularization (226) and
contributor to the development of neointimal hyperplasia (227). Cellular-response under
hypertension associated conditions has been well characterized by others (222,228,229) however,
characterization of cellular-response under elevated mechanical stain and diabetes-associated
chronic high glucose and insulin administration have not been reported previously in addition to
the non-availability to test platforms capable of combining all these patient-related complications.
In our previous investigations we have successfully demonstrated the influence of diabetes
associated chronic high glucose alone (192) and in combination with insulin administration
(previous chapter) on dedifferentiation of rat aortic smooth muscle cells (RASMCs) under dynamic
loading of physiologically relevant circumferential strain and stent-implant associated low wallshear-stress. At the clinical level, patients afflicted with diabetes also suffer from hypertension in
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a majority of cases however, due to inability of clinical studies to discern individual effects of these
complications, cellular-response during these patient-specific complications have not been
evaluated.
In the current investigation, we combined diabetes-associated chronic high glucose and insulin
administration with dynamic loading of hypertension-associated elevated mechanical strain and
stent-associated low wall-shear stress to capture the cellular-response under these clinically
relevant conditions more accurately and conceptualize an in vitro cell-response diabetichypertensive model. As an application of this model, we evaluated the efficacy of sirolimus, a
commonly employed in drug-eluting stents, to investigate if these patient-specific complications
altered sirolimus’ capacity to regulate and control phenotypic modulation of VSMCs. We
hypothesize that elevated mechanical strain with low-shear stress will result in greater
dedifferentiation of RASMCs and insulin administration will augment this effect. In addition, due
to greater proliferative effect of these patient-specific risk factors, equimolar concentration of
sirolimus will result in poor regulation of VSMC phenotype.
For this investigation, we compared the results of hypertensive loading with previously reported
results of insulin administration under normal circumferential loading with low shear stress and
have been labeled as normotensive-tensile-shear (NTS) or normotensive-tensile-shear with insulin
(NICTS) wherever required (previous chapter - DCTS and DICTS). In future, the currently
proposed model will be extremely useful in exploring molecular mechanisms involved in regulating
the cellular response under multiple patient-specific complications such as hypertension and
diabetes and can serve as an In-vitro test platform to evaluate the efficacy of novel molecular
therapies aimed at reducing In-stent restenosis in diabetic patients afflicted with hypertension and
requiring insulin administration prior to pre-clinical investigations.
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4.2: Materials and Methods:
4.2a. Isolation of rat aortic smooth muscle cells: Isolation of rat aortic smooth muscle cells: Rat
aortas were harvested from 9-10 weeks old female Sprague-DawleyTM rats using a modified version
of a previously published protocol (193) and was approved by Clemson University Institutional
Animal Care and Use Committee (IACUC). Briefly, aorta isolated from rat, was transferred back
to the laboratory and immediately rinsed with 1x sterile Dulbecco’s phosphate buffered solution
(DPBS; Cellergo, 21-031-CV) at 37 0C for 1-2 minutes in order to remove blood clots and any
unwanted tissue. Aorta were subsequently treated with Collagenase type-II (300U/mL,
Worthington 4176) in sterile Dulbecco’s modified essential medium (DMEM with 25 mM DGlucose; Corning 10-013-CM) for 12-15 minutes to enable enzymatic degradation of the
adventitial layer. Subsequently, using straight and angular forceps, tears in the adventitial layer
were created to facilitate its easy removal. After successfully removing the adventitial layer, aorta
was split open along its longitudinal axis thus, allowing easy scraping on the luminal side to remove
the endothelial monolayer. Multiple 1x DPBS rinses were performed to ensure removal of any
loose cells and tissue after which, aorta was chopped into small sections (about 1mm2) and
subjected to another enzymatic digestion containing type I collagenase - 10mg/mL, elastase (10
U/mL, Worthington 2292) treatment for 3-4 hours under gentle shaking conditions at 37 0C thus
allowing complete dissolution of the extracellular matrix of the medial layer. At the end of
enzymatic digestions, the suspension was centrifuged and cells were transferred to T-25 flasks in
DMEM (containing 25 mM D-Glucose) supplemented with 10% fetal bovine serum (FBS; Corning
35-010-CV) and 1% Antibiotic-Antimycotic agent (Penicillin/Streptomycin; Cellgro 30-004-CI).
The primary cell line was incubated for about a week before passaging and subsequent passaging
was performed every two weeks until passage 4. Cells were recruited at passage 4 for all
experiments, in order to remove any passage-associated variability.
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4.2b. Preparation of silicone membranes and Cell seeding: : Two baseplates were used providing
a total sample size of 6 test specimens per experiment, as described previously (192). Biomedicalgrade silicone membrane of 0.015-inch thickness (0.15” NRV G/G 40D, Specialty Manufacturing
Inc., MI) were cut to fit the custom cell-culture assembly (Figure 6a) which were coated with type
1 collagen using Teflon ring (2.75 cm2 inner cross-sectional area and 1.2 cm height) centered on
the silicone surface exactly above the loading post (Figure 6b). To minimize friction between the
loading post and the silicone membrane, 0.2 ml of silicone lubricant (Loctite, 51360) was
distributed evenly on the loading-post under aseptic conditions.

The simulator design enables user to accommodate three of such assemblies on each baseplate (3
loading stations per baseplate) and with two baseplates it provides a total sample size of 6 test
specimens. System sterilization is performed by subjecting baseplate to an overnight UV treatment
whereas all detachable parts are autoclaved. Each sandwich assembly was placed on a loading post
with 0.2 cc of silicone lubricant (Loctite, 51360) distributed evenly in between. Sterile Teflon rings
(2.75 cm2 inner cross-sectional area and 1.2 cm height) were then centered on the silicone surface
exactly above the loading post. The surface area confined by the Teflon ring was coated with
collagen type-I (Advanced Biomatrix, 5005B) at a final concentration of 50 µg/mL using deionized
water.

Passage 4 VSMCs cultured in media containing 25 mM D-Glucose were trypsinized (Corning, 25050-CI) and counted using scepter cell-counter (Millipore, PHCC00000) and seeded at a density
of 3.6 x 104 cells/cm 2 or 100,000 cells per well/loading station and allowed to attach and spread
for 36 hours in cell culture media containing 10% FBS, 1% Ab/Am and 25 mM dimethyl sulfoxide
(DMSO). After 36 hours, media was changed to DMEM containing 1% FBS, 1% Ab/m and 1%
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Dextran (Sigma, 9004-54-0) to induce quiescence and adjust media viscosity respectively. Cells
were subjected to media supplemented with 10 ng/mL insulin (Sigma, I0516) during induction of
quiescence and mechanical loading to represent insulin administration and to represent sirolimus
treatment, cells were subjected to mechanical loading in media supplemented with 10 ng/mL
sirolimus dissolved in DMSO (Table 8). Exact concentration of sirolimus in the vasculature is not
properly defined however, previous investigations with sirolimus-eluting stents have demonstrated
sirolimus concentrations in the blood to fall within range after deployment in animal models (230).
Final concentration of DMSO was 25 mM in all treatments to normalize any effect. Upon
completion for every loading condition for each respective treatment, cells were rinsed with sterile
1x DPBS for 1-2 minutes and were subsequently detached using 1mL/well of trypsin-EDTA
treatment and assayed.
Table 8 – Treatments and loading conditions
Normotensive-strain Shear (NTS)
Treatment
(0-7 % cyclic strain, 0.5 Hz for 24

(D)

DMSO Control

Loading

Hypertensive-strain Shear (HTS) (015 % cyclic strain, 0.5 Hz for 24

hours with shear from flow ~ 0.3

hours with shear from flow ~ 0.3

dynes.cm-2)

dynes.cm-2)

NTS: Cells in media containing 25

HTS: Cells in media containing 25

mM DMSO during seeding (36

mM DMSO during seeding (36

hours), induction of quiescence (24

hours), induction of quiescence (24

hours) and normotensive-loading (24

hours) and hypertensive-loading (24

hours) (Previous chapter)

hours).
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(DS)
(DI)
(DIS)

+ 10 ng/mL Sirolimus
(10 ng/mL)
(10 ng/mL) + 10 ng/mL Sirolimus

DMSO
DMSO + Insulin
DMSO + Insulin

NTSS: Cells in media containing 25

HTSS: Cells in media containing 25

mM DMSO during seeding (36 hours)

mM DMSO during seeding (36

and induction of quiescence (24

hours) and induction of quiescence

hours), 25 mM DMSO + 10 ng/mL

(24 hours), 25 mM DMSO + 10

sirolimus during normotensive-

ng/mL sirolimus during hypertensive-

loading (24 hours).

loading (24 hours).

NITS: Cells in media containing 25

HITS: Cells in media containing 25

mM DMSO during seeding (36

mM DMSO during seeding (36

hours), 25 mM DMSO + 10 ng/mL

hours), 25 mM DMSO + 10 ng/mL

insulin during induction of quiescence

insulin during induction of quiescence

(24 hours) and normotensive-loading

(24 hours) and hypertensive-loading

(24 hours). (Previous chapter)

(24 hours).

NITSS: Cells in media containing 25

HITSS: Cells in media containing 25

mM DMSO during seeding (36

mM DMSO during seeding (36

hours), 25 mM DMSO + 10 ng/mL

hours), 25 mM DMSO + 10 ng/mL

insulin during induction of quiescence

insulin during induction of quiescence

(24 hours); 25 mM DMSO + 10

(24 hours); 25 mM DMSO + 10

ng/mL insulin + 10 ng/mL sirolimus

ng/mL insulin + 10 ng/mL sirolimus

during normotensive-loading (24

during hypertensive-loading (24

hours).

hours).

4.2c. Mechanical Loading: Cells were subjected to either physiological tensile strain (0-7% at 0.5
Hz) and low wall-shear stress (NTS, ~0.30 dynes.cm-2) or hypertensive tensile strain (0-15% at 0.5
Hz) and low wall-shear stress (HTS, ~0.30 dynes.cm-2), with treatments and loadings summarized
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in table 8. Cyclic strain was applied using FlexCell-3000TM system (Flexcell International, NC)
where shear stress was provided by externally supplied flow at 350 mL/min using a peristaltic pump
(Cole-Parmer). All simulations were performed at 37 0C in an incubator (Fisher Scientific).

4.2d. Cell-cycle analysis: Cell cycle analysis was performed using propidium iodide staining
method using the Guava cell-cycle flow cytometric assay (Millipore, 4500-0220). Briefly, cells
were detached at the end of every simulation using trypsinized-EDTA and were centrifuged at 500x
g for 5 minutes. Subsequently, cells were rinsed in 1x DPBS and re-centrifuged for 5 minutes at
500x g. Cells were redissolved in 200 µL of 1x DPBS and fixed in ice-cold 70% ethanol with
gentle-intermittent shaking and stored at -20 0C for 48 hours at least. On the day of the assay, cells
were removed from ethanol, rinsed in 1x DPBS and resuspended in 200 µL of guava cell-cycle
reagent after which they were incubated in dark conditions for 30 minutes at room temperature.
Finally, cells were assayed for their distribution within the cell cycle with Guava HT flow
cytometer. For each sample, the threshold cellular count was set to 2000 events (195,196).

4.2e. Apoptosis analysis: Apoptotic analysis was performed using the TUNEL assay approach
where cells undergoing apoptosis were incorporated with fluorescently labeled dUTP and
subsequently assay for their intensity using Guava flow cytometer. Cells were detached and fixed
in 70% ethanol similarly to cell-cycle analysis, for measuring apoptotic index for all treatments and
on the day of the assay, cells were first incubated with a reaction mixture containing dUTP
monomers for 1 hour and subsequently incubated with Anti-BrDU antibody, according to
manufacturer’s protocol (Millipore 4500-0121) (196).
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4.2f. Cellular Hypertrophy: Measurement of cellular hypertrophy was performed as described
previously (192). Briefly, cells after each treatment were fixed and permeabilized with 0.2% Triton
X-100 in PBS following which cells were incubated with rhodamine-phalloidin (P1951, Sigma;
1:2000) and DAPI (1:2000) in PBS. Cells were imaged using fluorescent microscope (Digital
inverted microscope, EVOS f1, AMG). For each sample, five to six random field-of-view were
recorded and analyzed per sample, resulting in a total sample size of 180 per experimental group.
Cell area (indicative of cellular hypertrophy) and aspect ratio (major axis length to minor axis
length ratio) were measured using ImageJ software (NIH. Mean cell area (µm2) & aspect ratio were
measured and analyzed for a sample size of 180 per treatment (192).

4.2g. Protein extraction and Western blotting: Whole cell lysates were prepared from the cells at
the end of each simulation using extraction buffer (20 mM Tris 1% SDS, 0.5% Triton and 10 µL/mL
protease inhibitor cocktail, Sigma P 8340). Total protein concentration was calculated using BCAassay kit (Life Technologies, 23225) using BSA know standards as described by manufacturer.
SDS-PAGE was performed using Mini-PROTEAN TGX 10% precast-gels (BioRad 4561034). For
each well, 10 µg of total protein was loaded using 5x loading buffer and electrophoresis was
performed at 110 V for 90 minutes. Protein samples were subsequently transferred to PVDF
membranes (BioRad 1620177) at 100V for 75 minutes under ice-cold conditions. Blots were
blocked with 3% BSA in PBS and were probed with primary antibodies overnight at 4 0C (SM αactin ab 119952, 1:500; SM-22α, ab10135 1:1500; α-tubulin, ab7291 1:1500; p-AKT 4060s Cell
signaling technologies 1:1000; p-ERK ½ 4370s Cell signaling technologies 1:1000). Luminol was
used as a chemiluminescence-substrate (Santa Cruz, SC-2048) reagent prior to blot-imaging.
Densitometric analysis was performed using ImageJ software to quantify the amount of protein
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expressed. Prior to analysis, all protein bands were normalized with α-tubulin, which was the
loading control (192).
4.2h. Statistical analysis: Statistical Analysis was performed with One-way ANOVA and Tukey’s
HSD post hoc for all data sets with 0.05 level of significance (α = 0.05). All tests were performed
with JMP 12 pro and plots were created with OriginPro 2017.
4.3: Results:
4.3a. Cell-cycle analysis: In order to evaluate the effects of hypertensive mechanical loading and
efficacy of sirolimus, cells were assayed using the Guava cell-cycle assay. Distribution of cells
within the cell-cycle is shown in figure 20 with treatments in columns and mechanical loading in
rows. Percentage of cells in all the cell-cycle phase are summarized in table 9.

Table 9: Cell-cycle results for aim 2

Control

% Cells in
G1/G0-phase
78.41 ± 2.06

% Cells in
S-phase
6.63 ± 1.07

% Cells in
G2/M-phase
11.95 ± 1.63

Hypertensive

Control

63.55 ± 3.62

5.46 ± 0.74

30.98 ± 4.08

HTS

Normal

Insulin

53.1 ± 3.560

9.43 ± 1.76

37.46 ± 2.25

NITS

Hypertensive

Insulin

45.95 ± 3.19

8.7 ± 1.94

35.35 ± 2.62

HITS

89.81 ± 5.11

7.05 ± 0.91

3.18 ± 0.69

NTSS

77.45 ± 5.04

3.9 ± 0.94

18.64 ± 2.69

HTSS

69.67 ± 4.64

11.76 ± 2.58

28.56 ± 4.49

NITSS

62.07 ± 4.56

7.15 ± 0.61

30.78 ± 1.20

HITSS

Loading

Treatment

Normal

Normal

Hypertensive

Normal

Hypertensive

Control +
Sirolimus
Control +
Sirolimus
Insulin +
Sirolimus
Insulin +
Sirolimus
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Sample
NTS

Figure 20: Treatment
and loading-wise cellcycle distribution of
cells. Each sample was
assayed for 2000 cells.
First peak represents %
cells in the G1/G0 phase
whereas second peak
represents % cells in
G2/M phase. All cells in
between these two
distinct peaks were
categorized in the sphase.

From these results, it is evident that application of elevated mechanical strain (associated with
hypertension) led to significantly reduced number of cells in the G1/G0 phase control (p-value
<0.0001 for NTS vs HTS) as well as insulin (p-value <0.0001 for NITS vs HITS) whereas influence
of insulin can be appreciated from even lower percentage of cells in the G1/G0 phase with insulin
treatment under hypertensive loading (p-value < 0.0001 for NITS vs HITS). With administration
of sirolimus, there was a significant increase in the percentage of cells in the G1/G0 phase across
all treatments (p-value < 0.0001 for NTSS vs NTS; HTSS vs HTS; NITS vs NITSS; HITSS vs
HITS) however, presence of insulin and application of elevated mechanical strain still resulted in
significantly lower number of cells in the G1/G0 phase (p-value < 0.0001 for NTSS vs HTSS;
NITSS vs HITSS) with insulin combined with hypertensive loading resulting in the lowest number
of cells in the G1/G0 (Figure 21).
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Figure 21: Treatmentwise percentage of cells
in the G1/G0 phase
within each mechanical
loading; Values
represented as Mean ±
SD for every treatment
(n=6 for each). ‘*’
represents statistical
significance (p-value <
0.05) in comparison to
respective normotensive
control; ‘#’ represents
statistical significance
(p-value < 0.05) in
comparison to respective
no-drug treatment.

Figure 22: Treatmentwise percentage of cells
in the S-phase within
each mechanical
loading; Values
represented as Mean ±
SD for every treatment
(n=6 for each). ‘*’
represents statistical
significance (p-value <
0.05) in comparison to
respective normotensive
control.
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Figure 23: Treatmentwise percentage of cells
in the G2/M-phase
within each mechanical
loading; Values
represented as Mean ±
SD for every treatment
(n=6 for each). ‘*’
represents statistical
significance (p-value <
0.05) in comparison to
respective normotensive
control; ‘#’ represents
statistical significance
(p-value < 0.05) in
comparison to
respective no-drug
treatment.

Reduction in percentage of cells in the G1/G0 phase corresponded to increase in percentage of cells
in the S (figure 22) and G2/M phases (figure 23). As evident from the results application of
hypertensive mechanical strain resulted in significantly greater percentage of cells in the S-phase
for both control (p-value < 0.0001 for NTS vs HTS) and insulin treatment (p-value < 0.0001 for
NITS vs HITS) and significantly greater percentage of cells in the G2/M phase for both control (pvalue < 0.0001 for NTS vs HTS) and insulin (p-value < 0.0001 for NITS vs HITS) treatment as
well. Treatment of these groups with sirolimus markedly reduced the percentage of cells in the
G2/M phase for all treatments and loadings (p-value < 0.0001 for NTSS vs NTS; NITSS vs NITS;
HTSS vs HTS; HITSS vs HITS) however, differences in the S-phase were non-significant.
Collectively, these results indicate a pro-proliferative effect of elevated mechanical strain thus,
indicating greater phenotypic modulation of RASMCs due to hypertension-associated mechanical
forces. Further, in conformity with previously results (previous chapter), insulin treatment resulted
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in greater percentage of cells in the G2/M phase. Combined with hypertensive-loading, insulin
administration led to the lowest percentage of cells in the G1/G0 phase with corresponding increase
in the G2/M phase consequently demonstrating a corroborating effect of both hypertensive-loading
and insulin treatment.

4.3b. Apoptosis analysis: Cells undergoing apoptosis were estimated by measuring the percentage
of cells stained positive for TUNEL staining with flow cytometric assay. Distribution of percentage
of cells undergoing apoptosis is shown in figure 24. Percentage of cells undergoing apoptosis for
each treatment are summarized in table 10. As evident from the results, (figure 25), insulin
treatment resulted in significantly reduced number of cells undergoing apoptosis (p-value < 0.0001
for NITS vs NTS; HITS vs HTS). Hypertensive mechanical loading led to significantly greater
number of cells undergoing apoptosis for both the control (p-value < 0.0001 for HTS vs NTS) and
insulin (p-value < 0.0001 for HITS vs NITS). Supplementation of sirolimus reduced the overall
number of cells undergoing apoptosis for both control (p-value < 0.0001 for NTSS vs NTS) and
insulin (p-value < 0.0001 for NITSS vs NITS) under normotensive conditions as well as for both
control (p-value < 0.0001 for HTSS vs HTS) and insulin (p-value < 0.0001 for HITSS vs HITS)
treatments under hypertensive loading conditions.
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Figure 24: Treatment and loading-wise TUNEL positive cell-distribution. Each sample was
assayed for 2000 cells. First peak represents % cells in the negative for TUNEL statin whereas
second peak represents % cells positive for TUNEL stain. All cells in between these two distinct
peaks were categorized in the s-phase.
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Table 10: TUNEL results for aim 2
Loading

Treatment

% Apoptotic cells
(Mean ± SD)

Sample

Normal

Control

29.12 ± 0.85

NTS

Hypertensive

Control

54.57 ± 1.01

HTS

Normal

Insulin

29.19 ± 2.49

NITS

Hypertensive

Insulin

77.49 ± 6.63

HITS

Normal

Control + Sirolimus

19.11 ± 3.40

NTSS

Hypertensive

Control + Sirolimus

46.56 ± 2.97

HTSS

Normal

Insulin + Sirolimus

22.07 ± 2.58

NITSS

Hypertensive

Insulin + Sirolimus

57.72 ± 2.56

HITSS

Figure 25: Treatment-wise percentage of cells undergoing apoptosis within each mechanical
loading; Values represented as Mean ± SD for every treatment (n=6 for each). ‘*’ represents
statistical significance (p-value < 0.05) in comparison to respective normotensive control;
‘#’ represents statistical significance (p-value < 0.05) in comparison to respective no-drug
treatment.
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4.3c. Hypertrophy analysis: RASMCs stained with rhodamine-phalloidin are shown in figure 26
and results for both cell-area and aspect-ratio are summarized in table 11. Cell area measurements
were observed to be for NTS; for HTS; for NITS; for HITS; for NTSS; for HTSS; for NITSS; for
HITSS.

Figure 26: Rhodamine-phalloidin stained images with treatments as rows and mechanical
loadings as columns. Scale-bar 400 µm
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Table 11: Cell-area and aspect-ratio results for aim 2
Loading

Treatment

Normal

Control

Cell Area
(sq.µm)
Mean ± SD
2994.73 ± 65.75

Hypertensive

Control

4356.92 ± 650.87

1.39 ± 0.14

HTS

Normal

Insulin

4362.94 ± 88.67

1.84 ± 0.23

NITS

Hypertensive

Insulin

6775.89 ± 450.05

0.99 ± 0.17

HITS

2690.06 ± 270.01

1.96 ± 0.26

NTSS

3119.34 ± 289.04

1.46 ± 0.21

HTSS

3507.23 ± 287.65

1.58 ± 0.29

NITSS

5520.31 ± 509.89

1.09 ± 0.13

HITSS

Normal

Hypertensive

Normal

Hypertensive

Control +
Sirolimus
Control +
Sirolimus
Insulin +
Sirolimus
Insulin +
Sirolimus

Aspect
Ratio
Mean ± SD
2.31 ± 0.05

Sample
NTS

From figure 27, it can be appreciated that application of hypertensive mechanical strain led to
significantly greater cell area (p-value < 0.0001 for HTS vs NTS) and insulin treatment further led
to larger cell-area (p-value < 0.0001 for HITS vs NITS) thus, indicating that application of elevated
mechanical strain leads to a relatively hypertrophic response which is further exaggerated by insulin
treatment. Sirolimus treatment did reduce the cell-area across all treatments (p-value <0.0001 for
NTSS vs NTS; HTSS vs HTS; NITSS vs NITS; HITSS vs HTS) however, cell area was greater for
insulin treatment combined with hypertensive mechanical loading despite insulin treatment as
compared to control during normotensive loading (p-value < 0.0001 for HITSS vs NTSS).
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Figure 27: Treatmentwise Cell area (sq. µm)
within each mechanical
loading; Values
represented as Mean ±
SD for every treatment
(n=6 for each with 180
cells per sample). ‘*’
represents statistical
significance (p-value <
0.05) in comparison to
respective normotensive
control; ‘#’ represents
statistical significance
(p-value < 0.05) in
comparison to
respective no-drug
treatment.
Corresponding aspect ratio measurements were observed to be Aspect ratio results (figure 28) were
in accordance with cell-are measurements where application of hypertensive mechanical strain
results in significantly reduced aspect ratio for control (p-value < 0.0001 for HTS vs NTS) and
insulin treatment (p-value < 0.0001 for HITS vs NITS) with significantly lower aspect ratio for
insulin treated samples under hypertensive loading as compared to hypertensive control treatment
(p-value < 0.0001 for HITS vs HTS). Further, sirolimus treatment led to an overall increase in the
mean aspect ratio for all treatments under normotensive (p-value < 0.0001 for NTSS vs NTS;
NITSS vs NITS) and hypertensive loading (p-value < 0.0001 for HTSS vs HTS; HITSS vs HITS).

105

Figure 28: Treatmentwise aspect-ratio
within each
mechanical loading;
Values represented as
Mean ± SD for every
treatment (n=6 for
each with 180 cells per
sample). ‘*’ represents
statistical significance
(p-value < 0.05) in
comparison to ‘control
or DMSO’ for every
loading with one-way
ANOVA and Tukey’s
HSD post-hoc
comparison.

In summary, these results demonstrate a relatively greater synthetic state of RASMCs subjected to
hypertensive loading due to greater cellular hypertrophy as indicated by significantly greater cell
area and reduced aspect ratio. Further, these results demonstrate the combined influence of insulin
administration and hypertensive loading since this particular groups had the greatest cell area
corresponding to lowest aspect ratio.
4.3d. Protein expression: Phenotypic dedifferentiation of RASMCs was evaluated by comparing
α-SM actin and SM22α expression between different loadings and treatments. α-SM actin results
(figure 29) reveal that subjecting cells to hypertensive loading to greater dedifferentiation of
RASMCs as compared to normotensive loading for both control (p-value < 0.0001 for HTS vs
NTS) and insulin treatment (p-value < 0.0001 for HITS vs NITS). In addition, effects of insulin
can be appreciated from significantly reduced expression of α-SM actin under hypertensive loading
in comparison to normotensive loading of insulin treated cells (p-value < 0.0001 for HITS vs NITS)
and hypertensive loading of control treatment (p-value < 0.0001 for HITS vs HTS) thus, indicating
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greater dedifferentiation of RASMCs with hypertensive loading which is further enhanced with
insulin treatment.

Figure 29: Treatment-wise α-SM actin expression normalized to α-Tubulin expression within
each mechanical loading; Values represented as Mean ± SD for every treatment (n=6 for each).
‘*’ represents statistical significance (p-value < 0.05) in comparison to respective
normotensive control; ‘#’ represents statistical significance (p-value < 0.05) in comparison to
respective no-drug treatment.

SM22α was another protein marker employed to evaluate the effects of treatment and loading on
phenotypic modulation of RASMCs. Consistent with actin expression, SM22α expression results
(figure 30) indicate significantly reduced expression of SM22α with hypertensive loading in
comparison to normotensive loading with control (p-value < 0.0001 for HTS vs NTS) and insulin
treatment (p-value < 0.0001 for HITS vs NITS). Further, in the presence of insulin hypertensive
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loading greatly reduced SM22α expression in comparison to normotensive insulin treated cells (pvalue < 0.001 for HITS vs NITS). Sirolimus treatments resulted in significantly greater SM22α
expression across all treatments under normotensive and hypertensive loading albeit, hypertensive
loading did not result in significantly reduced expression of SM22α during insulin treatment with
sirolimus. These results indicate significantly reduced expression of contractile-state associated
proteins – α-SM actin and SM22α due to hypertensive loading and in combination with insulin
treatment, hypertensive loading led to greater dedifferentiation of RASMCs as indicated by reduced
expression of contractile-state associated proteins. Further, sirolimus treatment did improve the
cellular outcome in control treatment under normotensive and hypertensive loading, it only
controlled dedifferentiation for insulin treated cells under normotensive loading but not
hypertensive loading.
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Figure 30: Treatment-wise SM22α expression normalized to α-Tubulin expression within
each mechanical loading; Values represented as Mean ± SD for every treatment (n=6 for
each). ‘*’ represents statistical significance (p-value < 0.05) in comparison to respective
normotensive control; ‘#’ represents statistical significance (p-value < 0.05) in comparison to
respective no-drug treatment.
Phosphorylation of ERK ½ is a known molecular effect during cellular proliferation and thus were
compared for different loadings and treatments. Results of p-ERK ½ expression (figure 31) indicate
that hypertensive loading led to significantly greater expression of p-ERK ½ for both control (pvalue < 0.0001 HTS vs NTS) and insulin treatment (p-value < 0.0001 for HITS vs NITS) thus,
indicating direct growth promoting effects of hypertensive loading. Further, insulin treatment led
to significantly greater expression of p-ERK ½ normotensive (p-value < 0.0001 for NITS vs NTS)
as well as hypertensive loading (p-value < 0.0001 for HITS vs HTS) in comparison to control
treatment. Treatment with sirolimus resulted in reduced expression of p-ERK ½ for both control
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and insulin treatment under normotensive (p-value < 0.0001 for NTSS vs NTS; NITSS vs NITS)
as well as hypertensive (p-value < 0.0001 for HTSS vs HTS; HITSS vs HITS) loading.

Figure 31: Treatment-wise pERK 1/2 expression
normalized to α-Tubulin
expression within each
mechanical loading; Values
represented as Mean ± SD for
every treatment (n=6 for
each). ‘*’ represents statistical
significance (p-value < 0.05)
in comparison to respective
normotensive control; ‘#’
represents statistical
significance (p-value < 0.05)
in comparison to respective
no-drug treatment.

Hsp47 has been identified as an indirect marker of collagen expression which in turn indicates the
phenotypic modulation of RASMCs since synthetic phenotype is known to generate greater amount
of collagen. Hsp47 expression was evaluated for hypertensive loading only and results (figure 32)
demonstrate that insulin administration led to greater expression of Hsp47 as compared to control
under hypertensive loading (p-value < 0.0001 for HITS vs HTS and sirolimus successfully
controlled Hsp47 expression for both control (p-value < 0.0001 for HTSS vs HTS and insulin
treatments (p-value < 0.0001 for HITSS vs HITS). Greater expression of Hsp47 with insulin
treatment indicates greater dedifferentiation of RASMCs which in turn is reduced with sirolimus
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administration however, was still significantly higher for insulin treated cells despite sirolimus
treatment (p-value < 0.0001 for HITSS vs HITS).

Figure 32: Treatment-wise Hsp47
expression normalized to α-Tubulin
expression
within
hypertensive
loading; Values represented as Mean ±
SD for every treatment (n=6 for each).
‘*’ represents statistical significance
(p-value < 0.05) in comparison to
‘control or DMSO’ for every loading
with one-way ANOVA and Tukey’s
HSD post-hoc comparison.

Overall results from this investigation are summarized in table 12 in comparison to NTS group
where ‘*’ represents significantly different in comparison to NTS. Expression of Hsp47 was
evaluated for hypertensive loading only and hence ‘$’ represents Hsp 47 expression in comparison
to HTS loading. Results clearly indicate a significantly greater phenotypic modulation of RASMCs
due to hypertension-associated elevated mechanical strain across all treatments and this effect was
augmented by insulin administration as HITS demonstrated significant effect across all assays. In
addition, sirolimus successfully reduced phenotypic modulation of RASMCs and also
demonstrated significantly greater percentage of cells in the G1/G0 phase across all loadings
however results were significantly poorer during insulin administration.
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*
Insulin
(10 ng/mL)
Insulin
(10 ng/mL) +
Sirolimus
(10 ng/mL)

*

*

*
*

*

*

*

*

*

Group

*

*

Hsp 47

*

*

p-ERK
1/2

*

*

SM22α

*

Actin

*

Aspect
Ratio

Control +
Sirolimus (10
ng/mL)

*

Area

Control

TUNEL

Treatment

Cell
Cycle

Table 12: Summary of all treatment and loading-wise comparison. Each row represents
treatment; each column represents assay performed; “Group” column represents loading
condition. ‘*’ indicates significantly different results in comparison to NTS

*

HTS

*

NTSS

*

HTSS

*

*

*

*

*

*

*

*

*

*

*

*

*

*

NITS
$

HITS
NITSS

*

*

*

HITSS

Discussion:
Hypertension continues to significantly influence the prognosis of PCI procedures even in the age
of second generation drug eluting stents and patients afflicted with diabetes and hypertension
continue to suffer from higher rates of revascularization procedures (156,213). A direct
consequence of hypertension is elevated circumferential stress in the arterial wall and as a result,
vascular cells experience significantly higher circumferential forces (214,215). Previous
investigations have successfully explored the effects of hypertensive mechanical strain on
phenotypic modulation of vascular smooth muscle cells (216,218) however, effects of these forces
in patient-specific complications of chronic high glucose and insulin administration remains
unexplored. In the current study, we investigated the effects of hypertension-associated elevated
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mechanical strain and implant associated low wall-shear stress on chronic high glucose acclimated
RASMCs with or without insulin to capture the clinically relevant cellular-response more
accurately and conceptualize an in vitro diabetic-hypertensive model. As an application, we
explored the ability of sirolimus (10 ng/mL), a drug commonly used for drug-eluting stents, to
effectively regulate RASMC differentiation under the diseased conditions. Sirolimus was the drug
of choice for this study since clinical investigations have demonstrated sirolimus eluting stents to
be associated with lower late luminal loss and hence restenosis than paclitaxel (231). In addition,
multiple clinical trials have shown poorer outcomes of DES in diabetic patients especially those
requiring insulin administration and non-significant performance of second generation of DES in
diabetic patients (105,232,233). This is further complicated by elevated blood pressure which has
been clinically demonstrated to promote in-stent restenosis (69). Efficacy of sirolimus under these
patient-specific complications has not been performed previously and successfully demonstrates
the advantage of this model in comparison to conventional static approaches.

Results from the current investigation demonstrated that application of elevated mechanical strain
significantly reduced % cells in the G1/G0 phase and subsequently increased % cells in the S and
G2/M phase of the cell cycle for both control and insulin treatment (p-value < 0.0001 for HTS vs
NTS and HITS vs NITS) thus, indicating a proliferative cellular-response associated with elevated
mechanical strain. insulin administration led to significantly greater proliferative response in
comparison to control under normotensive loading (previous study) and in the current investigation,
hypertension-associated loading also resulted in significantly greater proliferative response of
RASMCs with insulin administration in comparison to control (p-value < 0.0001 for HITS vs HTS).
These results indicate a pro-proliferative response of hypertension-associated elevated mechanical
strain which in turn, exerts a corroborating effect with insulin administration. These results are in
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agreement with previous investigations where elevated mechanical strain was shown to enhance
proliferation of VSMCs (219–221) and further supported by a greater proliferative response to PCI
in spontaneously hypertensive rats (SHR) (227). Sirolimus is a commonly employed drug in stents
with an anti-proliferative effect on VSMCs (234) and in the current study demonstrated too
successfully reduce % cells in the S and G2/M phase of the cell cycle for both normal and
hypertensive loading under control and insulin treatments (p-value < 0.0001 for all NTSS vs NTS;
HTSS vs HTS; NITSS vs NITS; HITSS vs HITS) however, did not reduce proliferation of cells
under insulin treatment to levels comparable to control under normal (p-value < 0.0001 for NITSS
vs NTSS) and hypertensive loading (p-value < 0.0001 for HITSS vs HTSS). Thus, for equimolar
drug concentrations, sirolimus treatment did not result in similar proliferative response for control
and insulin treatment further underscoring the need to design and test novel anti-restenotic
treatments at cellular level under disease-associated conditions.
Cells were evaluated for apoptosis with TUNEL-staining with flow cytometry and results from the
current study indicate that hypertension-associated elevated mechanical strain resulted in
significantly greater % cells undergoing apoptosis for both control (p-value < 0.0001 for HTS vs
NTS) and insulin treatment (p-value < 0.0001 for HITS vs NITS). Previously, insulin
administration resulted in an overall decrease in the % cells positive for TUNEL (previous study)
and similar effects of insulin were observed under hypertensive loading as well where insulin
administration resulted in reduced % cells undergoing apoptosis in comparison to control (p-value
< 0.0001 for HITS vs HTS). These findings are in accordance with previous in vitro and animal
model investigations where hypertensive mechanical strain (222–224) and systemic hypertension
resulted in greater apoptosis of VSMCs in parallel to higher proliferation (235,236). Sirolimus is
known for not inducing apoptosis in smooth muscle cells, with prior evidence showing its prosurvival effect in vitro (237). Under hypertension-associated elevated mechanical strain, sirolimus
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treatment resulted in reduced % TUNEL-positive cells for both control (p-value < 0.0001 for HTSS
vs NTSS; HITSS vs NITSS) and insulin treatment with significantly lower apoptotic cells observed
for insulin (p-value < 0.0001 for HITSS vs HTSS). VSMC apoptosis is known to exaggerate the
inflammatory response post PCI procedure owing to activation of multiple pathways (238), which
may further increase the neointimal response while localized delivery of sirolimus, has been shown
to result significantly lower apoptotic response in rats (237), in part due to lowered inflammatory
response.
Cellular hypertrophy was estimated by indirect measures of comparing cell-area and aspect ratio
with results indicating significantly greater cell-area and correspondingly recued aspect ratio for
cells subjected to hypertension-associated elevated mechanical loading in comparison to
normotensive loading reported previously with insulin treatment resulting in significantly greater
hypertrophic response as compared to control treatment under hypertensive loading (p-value <
0.0001 for HITS vs HTS). Systemic hypertension is known to induce hypertrophy in various tissue
and organs including vessel-wall (237) in addition to tissue hypertrophy observed in SHR animal
model of hypertension (239) thus, validating results from the current study with previous findings.
In addition, Sirolimus treatment successfully reduced overall hypertrophy significantly albeit,
hypertrophy was significantly greater for insulin treated cells (p-value < 0.0001 for HITSS vs
HTSS; NITSS vs NTSS) and hypertensive mechanical strain added to this effect (p-value < 0.0001
for HTSS vs NTSS) thus, demonstrating the combined effect of the two patient-specific
complications.
Expression levels of contractile-state associated markers directly indicate phenotypic modulation
in VSMCs and in the current study, expression levels of αSM-actin and SM22α were compared.
Results indicate significantly reduced expression of αSM-actin with hypertensive mechanical
loading for both the control and insulin treatment (p-value < 0.0001 for HTS vs NTS; HITS vs
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NITS) with significantly lowered αSM-actin expression levels for insulin under hypertensive
loading in comparison to control (p-value < 0.0001 for HITS vs HTS). Sirolimus treatment did not
results an in overall increase in αSM-actin expression for both control and insulin treatment across
all loadings however, insulin treated cells still expressed lower levels of αSM-actin in comparison
to controls with lowest levels for insulin treated hypertensive-loaded group. SM22α demonstrated
similar results with insulin treatment exhibiting significantly reduced SM22α levels in comparison
to control (p-value < 0.0001 for NITS vs NTS; reported previously) which were further lowered
with hypertensive mechanical loading (p-value < 0.0001 for HITS vs NITS). These results
demonstrate that application of hypertension-associated elevated mechanical strain results in
significant phenotypic modulation of chronic high glucose acclimated RASMC which in turn
results in greater dedifferentiation with insulin administration under these conditions. Consistent
with our results, previous investigations have also demonstrated recued expression of contractilestate associated markers in VSMCs subjected to elevated mechanical strain (216,218). Sirolimus
treatment did cause greater expression of SM22α across all treatments under hypertensive loading
however, results were still significantly lower for insulin treated cells in agreement with previous
investigations demonstrating induction of contractile phenotype with sirolimus treatment (237).
Expression levels of p-ERK ½ were compared to evaluate if proliferative effects of hypertensionassociated elevated mechanical strain is observable at a proteins level. Results indicate that
application of elevated mechanical strain resulted in significantly greater expression of p-ERK ½
for both control (p-value < 0.0001 for HTS vs NTS) and insulin (p-value < 0.0001 for HITS vs
NITS) under hypertensive loading and were consistent with normotensive results. insulin treatment
resulted in significantly greater expression of p-ERK ½ in comparison to control, for hypertensive
loading (p-value < 0.0001 for HITS vs HTS). With sirolimus treatments, there was an overall
decrease in the expression of p-ERK ½ for both control (p-value < 0.0001 for NTSS vs NTS; HTSS
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vs HTS) and insulin treatments (p-value < 0.0001 for NITSS vs NITS; HITSS vs HITS) under
normotensive and hypertensive loadings however, levels were significantly greater for insulin
treatment in comparison to control with hypertensive-mechanical loading adding to the effect (pvalue < 0.0001 for HITSS vs HTSS). These results indicate an overall pro-proliferative effect of
hypertension-associated elevated mechanical loading on chronic high glucose acclimated RASMCs
with insulin treatment further contributing to proliferation. Historically, investigations have
demonstrated significantly higher expression of p-ERK ½ in VSMCs subjected to elevated
mechanical strain and co-associated with proliferation (240–242).
Collagen expression is increased during VSMC dedifferentiation and elevated collagen a
characteristic marker of synthetic-state phenotype (243). Expression of Hsp47 was evaluated as
indirect estimator of collagen production under hypertension-associated elevated mechanical strain,
as previously it has been demonstrated to be associated with increased collagen production (243).
Results indicate that insulin treatment led to significantly greater expression of Hsp47 as compared
to control under hypertensive mechanical strain (p-value < 0.0001 for HITS vs HTS) which were
subsequently reduced with sirolimus treatment to level similar to control treatment hence
demonstrating the efficacy of sirolimus in controlling Hsp 47 expression and thus, collagen
expression under disease-associated conditions. Clinically, patients requiring insulin administration
have been reported to have restenotic lesions rich in extracellular-matrix primarily composing of
collagen (243) with in vitro evidence of synthetic-state of VSMCs reported to secrete higher
amounts of collagen.
Overall, results from the current study demonstrate the significance of combining multiple patientspecific complications such chronic high glucose, insulin treatment and hypertension-associated
elevated mechanical strain with implant associated low wall-shear stress where, disease specific
conditions resulted in significantly higher proliferative behavior and relatively greater phenotypic
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modulation. Cells subjected to these conditions capture the clinically relevant cellular-response of
diabetic patients afflicted with hypertension and implanted with stents more accurately.

Conclusion:
In the current study, we hypothesized that application of hypertension-associated elevated
mechanical strain will result significantly greater phenotypic modulation and pro-proliferative
behavior of RASMCs with additive effect of inulin treatment. Current results support our
hypothesis since hypertensive-mechanical strain resulted significantly greater % cells in the S and
G2/M phase of the cell cycle, greater apoptosis, higher cellular hypertrophy estimated by cell-area
and aspect ratio, reduced expression of contractile-state associated markers αSM actin and SM22α
with concomitant increase in expression levels of p-ERK ½. Dedifferentiation was more
pronounced with insulin administration thus, illustrating the combined effects of mechanical
loading, diabetes associated chronic high glucose and insulin administration, and hypertensive
mechanical loading altogether on phenotypic modulation of RASMCs. As an application of the
model, we evaluated the efficacy of sirolimus (10 ng/mL) in controlling proliferation and
phenotypic modulation of RASMCs which indicated that equimolar drug concertation may not be
sufficient to control a greater proliferative response associated with these patient-specific
complications and necessitates a more targeted approach. In future, this model can be utilized to
explore the complex and intricate cellular pathway involved in executing these responses and
molecular targets can be tested in regulating VSMC phenotype for novel clinical solutions aimed
at improving outcomes of PCI in these patients.
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Chapter 5: Project conclusions and recommendations
5.1 Project Conclusions:
In the current dissertation project, patient-specific complication of insulin administration and
selective insulin resistance were combined with physiologically relevant circumferential strain and
stem-implantation associated low wall-shear stress to evaluate their effect on proliferation and
phenotypic modulation of RASMCs in order to propose an in vitro diabetic model which captures
the clinically relevant cellular-response more accurately than conventional unloaded/static studies.
With this model, it was successfully demonstrated that administration of insulin contributed to the
dedifferentiation of RASMCs as they demonstrated greater proliferative response under these
conditions combined with reduced expression levels of contractile-state associated proteins.
Selective insulin resistance with wortmannin was incorporated to represent experimental diabetes
in vitro however, current results indicate that selective inhibition of AKT phosphorylation did not
result in significantly different proliferative behavior which was subordinated with similar
expression levels of αSM actin and SM22α thus, necessitating further investigations into the
involvement of AKT pathway in mediating insulin resistance in vascular smooth muscle cells.
However, similarity of cellular response with insulin treatment with prior in vitro investigations
and animal studies validate our results and are in accordance with clinical observation of
exaggerated progression of neointimal lesions in diabetic patients requiring insulin administration
(Chapter 3).
In the second phase of this project, hypertension-associated elevated mechanical strain was
incorporated to combine another clinically significant risk factor of developing in-stent restenosis
with previously explored diabetes-associated insulin administration to evaluate proliferation and
phenotypic modulation of RASMCs under diabetic-hypertension associated conditions. Results
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successfully demonstrated that elevated mechanical strain associated with hypertension results
significantly greater dedifferentiation of chronic high glucose acclimated RASMCs and these
effects were further advanced with insulin administration thus, illustrating that insulin
administration under hypertension-associated elevated mechanical strain results in the highest level
of VSMC proliferation and dedifferentiation. Thus, with this experimental approach we were able
to successfully combine two of the most significant patient-specific risk factors with implant
specific mechanical forces and evaluate their influence on cellular-response (Chapter 4).
Clinically, sirolimus eluting stents are the preferred choice for high-risk patients in comparison to
paclitaxel stents however, studies have indicated that while SES performed better than paclitaxel
eluting stents – this performance benefit is not extended to diabetic patients. As an application, the
current diabetic-hypertensive model was applied to test the efficacy of equimolar sirolimus in
controlling and reducing RASMC-proliferation and phenotypic modulation. We successfully
demonstrated that under insulin administration, cells demonstrated a greater proliferative response
with reduced expression of contractile-state associated proteins even with sirolimus treatment and
hypertension-associated elevated mechanical strain further added to dedifferentiation of RASMCs
hence, providing a cellular-response based evidence which may be responsible for the clinical
differences in efficacy of sirolimus eluting stents in controlling neointimal hyperplasia for diabetic
and hypertensive patients (Chapter 4).
Future investigations with the current model can be performed to explore the molecular basis of
the cellular-response thus divulging greater molecular intricacies and can be utilized a test platform
for novel anti-restenotic drugs/molecular targets aimed at reducing in-stent restenosis in diabetic
patients requiring insulin administration with comorbidity of hypertension. Our proposed cellularresponse model is designed to capture the patient-associated complications and combine them with
stent-implant associated altered hemodynamics at an in vitro level thus, providing a robust test
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platform to evaluate novel drugs aimed at reducing in-stent restenosis in diabetic-hypertensive
patients implanted with stents and in the long-term will serve as a tool to reduce the overall time
required to test novel technologies by bridging the gap between in vitro and pre-clinical models
(figure 33).
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Clinical Problem: Higher neointimal
hyperplasia in diabetic patients requiring
insulin administration

Clinical Problem: Higher neointimal
hyperplasia in hypertensive patients with
augmented effects of insulin administration

Clinical Impact: Higher rates of target
lesion revascularization, more deaths and
higher healthcare costs

Recommended solution: Specific stents/balloons
addressing greater proliferation and phenotypic
modulation associated with diabetes and
hypertension

In-vitro concept technologies:
Specifically aiming to address
cell-related complications

~ 5-10 years
assuming
technology shows
promising results

Clinical Trials: Technologies
tested at clinical level

In-vivo/Pre-clinical models: Technologies
translated to disease-models which are
representative of human pathophysiology

In-vitro disease model: Captures clinically relevant patient
specific complications with implant-associated hemodynamic
alterations

Figure 33: Project conclusion flow chart
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5.2 Project Recommendations:
The dissertation project has successfully developed the relationship between cellularresponse and clinically relevant pathological stimuli in diabetic-hypertensive patients with
effects of these conditions on efficacy of sirolimus in controlling proliferation and
phenotypic modulation of vascular smooth muscle cells. The overall approach of modeling
diabetes-hypertension associated complications can be utilized for the following research
areas:
1. Response evaluation with human vascular smooth muscle cells: Disease related
conditions may be impacted by the source of cells incorporated for in vitro response
evaluation. Patient-specific response accuracy can be significantly increased by
isolating VSMCs from human arteries and utilizing them for the in vitro diabetichypertensive model. Further, this design can also be used for comparing the efficacy
of various anti-restenotic drugs in controlling VSMC-response towards improvement
and optimization of novel drug-eluting stents.

2. Extension to 3-dimensional cell culturing approach: Currently, various studies have
been conducted which have demonstrated a variable response between 2-dimensional
and 3-dimensional cell culturing approach. Using the approach utilized in our design,
3D cultures can be subjected to the diabetic-hypertensive conditions and hence, cellular
response between our results and 3D investigations can be compared to reduce the
current knowledge gaps associated with these approaches.

3. Application to tissue engineering: The future of cardiovascular intervention research
is driven by bench-to-bedside technological approaches with tissue engineering being
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the most useful approach for treating cardiovascular complications. Our modeling
approach of combining diabetes and hypertension can be utilized in evaluating the
response of stem cells with direct evidence of correlation between these complications
and cellular-differentiation. Further, scaffold characterization under these conditions
will improve the current understanding and will further optimize scaffolds for diabetichypertensive patients.

4. Mathematical modeling: Results from our research will be useful for investigators
working towards developing mathematical models of VSMC-response to pathological
stimuli and clinically relevant mechanical forces. Since current mathematical
approaches

are

currently

confined

to

modeling

without considering

the

biochemical/biological aspects of components, these mathematical models may be
significantly improved by incorporating our cause-effect results and hence will further
design-optimization of novel stents and other interventional approaches such as bypass
grafts.
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Appendix A: Vascular smooth muscle cell isolation, passaging, characterization and
maintenance of chronic high glucose conditions.
Thoracic aorta from 8-10 weeks old female Sprague-DawleyTM rats were isolated according to the
Institutional Animal Care and Use Committee (IACUC) at Clemson University. Aorta was
transferred back to the lab in sterile Dulbecco’s minimal essential medium containing 1%
Antibiotic/Antimycotic agent under ice-cold conditions. Next, the aorta was dissected under sterile
condition in 1x DPBS (at 37 0C) in order to successfully remove all the waste tissue attached to the
vessel and subsequently the vessel was subjected to enzymatic treatment with collagenase type I
for 15 minutes at 37 0C. This step ensures easier removal of the adventitia where it comes off like
a sock and does not damage the medial layer. Subsequently, the medial layer was scrapped on the
inside with the blunt side of a sterile scalpel to denude the endothelial monolayer and gently
scrapping was also performed on the outer side of the vessel to remove any remains of the
adventitial layer following which, blood vessel was chopped into square pieces of approximately 1
mm2 in size. Chopped tissue was then rinsed in fresh sterile 1x DPBS to remove any residual cells
and consequently was transferred to enzymatic solution 2 (Type I collagenase – 1 mg/mL, Elastase
– 0.25 mg/mL and Soybean trypsin inhibitor – 0.15 mg/mL) and incubated at 37 0C for 4-5 hours
with gentle shaking. After 4-5 hours, when the tissue pieces have been dissolved in the enzymatic
solution, the cell suspension was filtered through a cell strainer (100 µm pore size) following which
the cell suspension was centrifuged. After aspirating enzymatic solution, the pelleted cells were redissolved in the fresh media (DMEM + 10% FBS + 1% Ab/Am) and transferred to a T-25 cm2
flask. Cells were then incubated for 10-15 days with special attention to make sure that the flask is
not disturbed. Cells were passaged to bigger vessels as soon as confluence was achieved. Typically,
passaging was performed after 10-15 days for T-75 cm2 flasks and 20-25 days for T-175 cm2 flasks.
Passage 4 cells were eventually incorporated for all the experiments in order to ensure that any
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changes in phenotypic modulation are only associated with the treatment conditions and not due to
passaging. For all experiments and passaging cell culture media contained 4.5 g/L of D-Glucose in
order to replicate chronic high glucose exposure.
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Appendix B: Flexcell frequency-dependent stretch characterization.
In order to model the hypertension-associated cyclic stretch in vitro, the stretch profile was altered
to apply higher and clinically relevant levels of strain (~15%). To verify if the theoretical and
applied strain are within acceptable range, strain profiles were measured at different strains and
frequencies. Three rings were drawn on the silicone membrane where the first ring represented the
out periphery of the cell-seeded area (diameter = 19.05 mm; Black), the second ring represented
the middle cell-seeded area (diameter = 12.7 mm; Red) and finally the inner ring (diameter = 6.35
mm; Blue) as shown in Figure 34. Different strain regimes were applied to check if there were
differences in applied strain and theoretical values. Membrane behavior was recorded using two
camcorders and images were captured from the videos to measure circumferential strain and radial
distance.

A
B
C
Figure 34: PIP images for strain calibration experiment. A. relaxed/no-strain; B. 0-7% at 0.5
Hz; C. 0-7% 1 Hz
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Figure 35: Measured circumferential strain correlation with theoretical strain for three
different regions – black, red, blue.
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Values were measured for each respective zone (black, blue or red) for circumferential strain
and radial distance (figure 35) whereas compiled plots of individual region (blue, red or
black) for circumferential strain vs theoretical strain are in figure 36a and circumferential
strain vs radial distance in figure 36bIn order to estimate the averaged strain over the zone
starting at the center of the membrane extending until the black ring, measured values were
averaged for all zones and compiled separately for 0.5 Hz and 1 Hz (figure 36). Values for
data points are enlisted in the table 13.

Circumferential Strain (%)

Circumferential Strain vs. Theoretical Applied
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0

Average 1 Hz
Average 0.5 Hz

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Theoretical Applied (%)

Figure 36: Averaged (measured circumferential strain) correlation with theoretical strain
averaged for the entire membrane and plotted for 1 Hz (red) and 0.5 Hz (black).
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Table 12: Tabular values for circumferential strain for three different regions – black, red,
blue under 1 Hz and 0.5 Hz loading.
Frequency

Circumferential Strain

Theoretical

Radial Strain

Strain

Black

Red

Blue

Black

Red

Blue

0

0

0

0

0

0

0

7

5.21

13.63

5.96

3.61

5.57

4.19

15
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6.44

0.98

20

0.41
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0.23
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0

0

0

0

0

0
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8.53
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9.24
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13.49

10.14
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7.29

20.28
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5.48

20.72

23.21

20
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11.23

-1.38

10.91

14.07

1 Hz
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Figure 37: A- Compiled plots for measured strain vs theoretical strain of all three
zones.
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Figure 37: B - Compiled plots for measured strain vs radial distance of all three
zones.
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Both strain application frequencies demonstrated linear behavior in the physiologically relevant
range of 0-7 % strain however, beyond this point – applied strain was only linear for 0.5 Hz
frequency and not with 1 Hz in our custom vascular simulator. All measurements were recorded
under true-experiment like conditions, including using silicone lubricant. Thus, a theoretical 15%
strain would have resulted in ~ 5% applied strain with the current design and hence, would have
not represented hypertension-associated elevated mechanical strain. Subsequently, all experiments
were performed using 0.5 Hz frequency instead of 1 Hz.
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Appendix C: CAD drawings of modified cell-culture rings
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